Envista (NVST) 10-Q 30 Jul 20 2020 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jul. 03, 2020	Jul. 24, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 3, 2020
Document Transition Report	false
Entity File Number	001-39054
Entity Registrant Name	ENVISTA HOLDINGS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-2206728
Entity Address, Address Line One	200 S. Kraemer Blvd., Building E
Entity Address, City or Town	Brea,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92821-6208
City Area Code	714
Local Phone Number	817-7000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	NVST
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		159,393,769
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Central Index Key	0001757073

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019
Current assets:
Cash and equivalents	$ 822.4	$ 211.2
Trade accounts receivable, less allowance for credit losses of $30.6 and $22.8, respectively	306.4	443.6
Inventories, net	280.8	277.9
Prepaid expenses and other current assets	108.1	69.2
Total current assets	1,517.7	1,001.9
Property, plant and equipment, net	294.3	290.3
Operating lease right-of-use assets	188.9	200.1
Other long-term assets	75.2	74.4
Goodwill	3,333.8	3,306
Other intangible assets, net	1,255.3	1,285.6
Total assets	6,665.2	6,158.3
Current liabilities:
Short-term debt	253.5	3.9
Trade accounts payable	130.9	208
Accrued expenses and other liabilities	419.4	470.6
Operating lease liabilities	26.4	26.7
Total current liabilities	830.2	709.2
Operating lease liabilities	176	186
Other long-term liabilities	440.9	399.3
Long-term debt	1,722.2	1,321
Commitments and contingencies
Stockholders’ equity:
Preferred stock, no par value, 15.0 million shares authorized; no shares issued or outstanding at July 3, 2020 and December 31, 2019	0	0
Common stock - $0.01 par value, 500.0 million shares authorized; 159.4 million shares issued and 159.3 million outstanding at July 3, 2020; 158.7 million shares issued and outstanding at December 31, 2019	1.6	1.6
Additional paid-in capital	3,665.9	3,589.7
(Accumulated deficit) retained earnings	(17.6)	93.1
Accumulated other comprehensive loss	(156.5)	(144.2)
Total Envista stockholders’ equity	3,493.4	3,540.2
Noncontrolling interests	2.5	2.6
Total stockholders’ equity	3,495.9	3,542.8
Total liabilities and stockholders’ equity	$ 6,665.2	$ 6,158.3

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 30.6	$ 22.8
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	159,400,000	158,700,000
Common stock, shares outstanding (in shares)	159,300,000	158,700,000
Preferred shares authorized (in shares)	15,000,000	15,000,000
Preferred shares issued (in shares)	0	0
Preferred shares outstanding (in shares)	0	0

Condensed Consolidated and Comb

Condensed Consolidated and Combined Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Income Statement [Abstract]
Sales	$ 362	$ 712.1	$ 909.2	$ 1,371.8
Cost of sales	211.5	318.5	480.3	615.1
Gross profit	150.5	393.6	428.9	756.7
Operating expenses:
Selling, general and administrative	241.9	278	510.6	552.9
Research and development	16.5	39.7	51.2	83
Operating (loss) profit	(107.9)	75.9	(132.9)	120.8
Nonoperating income (expense):
Other income	0.1	1.3	0.2	1.4
Interest expense, net	(14.5)	0	(17.8)	0
(Loss) income before income taxes	(122.3)	77.2	(150.5)	122.2
Income tax (benefit) expense	(28.8)	15.7	(39.8)	22.8
Net (loss) income	$ (93.5)	$ 61.5	$ (110.7)	$ 99.4
(Loss) earnings per share:
Basic and diluted (in USD per share)	$ (0.59)	$ 0.48	$ (0.69)	$ 0.78
Average common stock and common equivalent shares outstanding:
Basic and diluted (in shares)	159.5	127.9	159.3	127.9

Condensed Consolidated and Co_2

Condensed Consolidated and Combined Statements of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (93.5)	$ 61.5	$ (110.7)	$ 99.4
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	33.1	31.2	(4.1)	(6.6)
Cash flow hedge adjustments	0	0	(8.9)	0
Pension plan adjustments	0.3	(0.7)	0.7	(0.6)
Total other comprehensive income (loss), net of income taxes	33.4	30.5	(12.3)	(7.2)
Comprehensive (loss) income	$ (60.1)	$ 92	$ (123)	$ 92.2

Condensed Consolidated and Co_3

Condensed Consolidated and Combined Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Former Parent Investment, Net	Accumulated Other Comprehensive Loss	Total Envista Equity	Noncontrolling Interests
Balance, beginning of period at Dec. 31, 2018		$ 0	$ 0	$ 0	$ 4,901.3	$ (78.2)	$ 4,823.1	$ 3.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity					4.1		4.1
Net (loss) income					37.9		37.9
Net transfers from Former Parent					24.3		24.3
Other comprehensive income (loss)						(37.7)	(37.7)
Changes in noncontrolling interests								(0.1)
Balance, end of period at Mar. 29, 2019		0	0	0	4,967.6	(115.9)	4,851.7	3.2
Balance, beginning of period at Dec. 31, 2018		0	0	0	4,901.3	(78.2)	4,823.1	3.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	$ 99.4
Other comprehensive income (loss)	(7.2)
Balance, end of period at Jun. 28, 2019		0	0	0	4,938.8	(85.4)	4,853.4	2.9
Balance, beginning of period at Mar. 29, 2019		0	0	0	4,967.6	(115.9)	4,851.7	3.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity					4.8		4.8
Net (loss) income	61.5				61.5		61.5
Net transfers from Former Parent					(95.1)		(95.1)
Other comprehensive income (loss)	30.5					30.5	30.5
Changes in noncontrolling interests								(0.3)
Balance, end of period at Jun. 28, 2019		0	0	0	$ 4,938.8	(85.4)	4,853.4	2.9
Balance, beginning of period at Dec. 31, 2019	3,542.8	1.6	3,589.7	93.1		(144.2)	3,540.2	2.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity			6.4				6.4
Net (loss) income				(17.2)			(17.2)
Other comprehensive income (loss)						(45.7)	(45.7)
Balance, end of period at Apr. 03, 2020		1.6	3,596.1	75.9		(189.9)	3,483.7	2.6
Balance, beginning of period at Dec. 31, 2019	3,542.8	1.6	3,589.7	93.1		(144.2)	3,540.2	2.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(110.7)
Other comprehensive income (loss)	(12.3)
Balance, end of period at Jul. 03, 2020	3,495.9	1.6	3,665.9	(17.6)		(156.5)	3,493.4	2.5
Balance, beginning of period at Apr. 03, 2020		1.6	3,596.1	75.9		(189.9)	3,483.7	2.6
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity			7.6				7.6
Equity component of convertible senior notes, net of financing costs and taxes			77.9				77.9
Purchase of capped calls related to issuance of convertible senior notes, net of taxes			(15.7)				(15.7)
Net (loss) income	(93.5)			(93.5)			(93.5)
Other comprehensive income (loss)	33.4					33.4	33.4
Changes in noncontrolling interests								(0.1)
Balance, end of period at Jul. 03, 2020	$ 3,495.9	$ 1.6	$ 3,665.9	$ (17.6)		$ (156.5)	$ 3,493.4	$ 2.5

Condensed Consolidated and Co_4

Condensed Consolidated and Combined Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019
Cash flows from operating activities:
Net (loss) income	$ (110.7)	$ 99.4
Noncash items:
Depreciation	19.6	19.8
Amortization	45.3	45
Allowance for doubtful accounts	11.6	3.1
Stock-based compensation expense	11.7	8.9
Restructuring charges	9	0
Impairment charges	10.3	0
Amortization of right-of-use assets	15.2	16.1
Amortization of debt discount and issuance costs	2.7	0
Change in trade accounts receivable, net	126.1	(16.1)
Change in inventories, net	(9.4)	(1.7)
Change in trade accounts payable	(77.1)	(24.4)
Change in prepaid expenses and other assets	(3)	(28)
Change in accrued expenses and other liabilities	(90.8)	10.4
Change in operating lease liabilities	(18.1)	(19.8)
Net cash (used in) provided by operating activities	(57.6)	112.7
Cash flows from investing activities:
Acquisitions, net of cash acquired	(40.7)	0
Payments for additions to property, plant and equipment	(21.4)	(42.1)
Proceeds from sales of property, plant and equipment	0	0.4
All other investing activities	7.7	(0.2)
Net cash used in investing activities	(54.4)	(41.9)
Cash flows from financing activities:
Proceeds from issuance of convertible senior notes	517.5	0
Payment of debt issuance and other deferred financing costs	(17.3)	0
Proceeds from revolving line of credit	249.8	0
Repayment of borrowings	(0.1)	0
Purchase of capped calls related to issuance of convertible senior notes	(20.7)	0
Proceeds from stock option exercises	5	0
Net transfers to Former Parent	0	(70.8)
All other financing activities	(1.1)	0
Net cash provided by (used) in financing activities	733.1	(70.8)
Effect of exchange rate changes on cash and equivalents	(9.9)	0
Net change in cash and equivalents	611.2	0
Beginning balance of cash and equivalents	211.2	0
Ending balance of cash and equivalents	822.4	0
Supplemental data:
Cash paid for interest	16.8	0
Cash paid for taxes	14.2	11.7
ROU assets obtained in exchange for operating lease obligations	$ 4.3	$ 12.2

Business and Basis of Presentat

Business and Basis of Presentation	6 Months Ended
	Jul. 03, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	BUSINESS AND BASIS OF PRESENTATION Separation and Initial Public Offering Envista Holdings Corporation (together with its subsidiaries, “Envista” or the “Company”) was formed as a wholly-owned subsidiary of Danaher Corporation (“Danaher” or “Former Parent”). Danaher formed Envista to ultimately acquire, own and operate the Dental business of Danaher. On September 20, 2019, the Company completed an initial public offering (“IPO”) resulting in the issuance of 30.8 million shares of its common stock (including shares issued pursuant to the underwriters’ option to purchase additional shares) to the public, which represented 19.4% of the Company’s outstanding common stock, at $22.00 per share, the initial public offering price, for total net proceeds, after deducting underwriting discounts and commissions, of $643 million . In connection with the completion of the IPO, through a series of equity and other transactions, Danaher transferred substantially all of its Dental business to the Company. As consideration for the transfer of the Dental business to the Company, the Company paid Danaher approximately $2.0 billion , which included the net proceeds from the IPO and the net proceeds from term debt financing, as further discussed in Note 13 , and issued to Danaher 127.9 million shares of the Company’s common stock. The transactions described above related to the transfer of the Dental business are collectively referred to herein as the “Separation.” On November 15, 2019, Danaher announced an exchange offer whereby Danaher stockholders could exchange all or a portion of Danaher common stock for shares of the Company’s common stock owned by Danaher. The disposition of the Company’s shares (the “Split-Off”) was completed on December 18, 2019 and resulted in the full separation of the Company and disposal of Danaher’s entire ownership and voting interest in the Company. Business Overview The Company provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a worldwide provider of a broad range of dental implants, orthodontic appliances, general dental consumables, equipment and services and is dedicated to driving technological innovations that help dental professionals improve clinical outcomes and enhance productivity. The Company operates in two business segments: Specialty Products & Technologies and Equipment & Consumables. The Company’s Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Company’s Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; handpieces and associated consumables; treatment units and other dental practice equipment; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products. Basis of Presentation For periods after the Separation, the financial statements are prepared on a consolidated basis. Prior to the Separation, the Company operated as part of Danaher and not as a separate, publicly-traded company and the Company’s financial statements are combined, have been prepared on a stand-alone basis and are derived from Danaher's consolidated financial statements and accounting records. The Condensed Consolidated and Combined Financial Statements reflect the financial position, results of operations and cash flows related to the Dental business that was transferred to the Company. All revenues and costs as well as assets and liabilities directly associated with the business activity of the Company are included as a component in the financial statements. Prior to the Separation, the financial statements also included allocations of certain general, administrative, sales and marketing expenses and cost of sales from Danaher’s corporate office and from other Danaher businesses to the Company and allocations of related assets, liabilities and Danaher’s investment, as applicable. The allocations were determined on a reasonable basis; however, the amounts are not necessarily representative of the amounts that would have been reflected in the financial statements had the Company been an entity that operated independently of Danaher. Related-party allocations are discussed further in Note 21. Prior to the Separation, the Company was dependent upon Danaher for all of its working capital and financing requirements under Danaher’s centralized approach to cash management and financing of its operations. Financial transactions relating to the Company were accounted for through the Former Parent investment, net account of the Company. Accordingly, none of Danaher’s cash, cash equivalents or debt was assigned to the Company in these financial statements for the periods prior to the Separation. Former Parent investment, net, which included retained earnings, represented Danaher’s interest in the recorded net assets of the Company. Prior to the Separation, all significant transactions between the Company and Danaher have been included in the accompanying Condensed Consolidated and Combined Financial Statements. Transactions with Danaher are reflected in the accompanying Condensed Consolidated and Combined Statements of Changes in Equity as “Net transfers to Former Parent.” In connection with the Separation, the Former Parent investment, net balance was redesignated within equity and allocated between common stock and additional paid-in capital based on the number of the Company’s common shares outstanding at the Separation. In periods subsequent to the Separation, the Company may make adjustments to balances transferred at the Separation date and may record additional adjustments in the future. Any such adjustments are recorded through additional paid-in capital in equity. All significant intercompany accounts and transactions between the businesses comprising the Company have been eliminated in the accompanying Condensed Consolidated and Combined Financial Statements. The Condensed Consolidated and Combined Financial Statements included herein have been prepared by the Company without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The accompanying Condensed Consolidated and Combined Financial Statements contain all adjustments (consisting of only normal recurring adjustments and reclassifications to conform to current year presentation) necessary to present fairly the financial position of the Company as of July 3, 2020 and December 31, 2019, and its results of operations for the three and six month periods ended July 3, 2020 and June 28, 2019 and cash flows for the six month periods ended July 3, 2020 and June 28, 2019. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s combined financial statements and accompanying notes for the three years ended December 31, 2019, included in the Annual Report on Form 10-K filed by the Company on February 21, 2020. Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the novel coronavirus (“COVID-19”) pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict because of the dynamic and evolving nature of the crisis. In response to COVID-19 many dental associations recommended that dental practices delay elective procedures and only perform emergency procedures. As a result, t here have been widespread temporary closures of dental practices around the world due to the pandemic, except to perform emergency procedures, thereby preventing our end customers from conducting most or all business activities and significantly adversely impacting our sales . During the three months ended July 3, 2020, dental practices in the markets in which we operate have started to reopen, however, the average practice’s patient volume is below pre-COVID-19 levels. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or material global economic slowdown or global recession. Such economic disruption could have a material adverse effect on the Company as the Company’s customers curtail and reduce capital and overall spending. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remains uncertain. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the scope and duration of the pandemic, the extent and severity of the impact on the Company's customers, the measures that have been and may be taken to contain the virus or mitigate its impact, U.S. and foreign government actions to respond to the reduction in global economic activity, the ability of the Company to continue to manufacture and source its products, the impact of the pandemic and associated economic downturn on the Company’s ability to access capital if and when needed and how quickly and to what extent normal economic and operating conditions can resume, all of which are uncertain and cannot be predicted. Even after the COVID-19 outbreak has subsided, the Company may continue to experience materially adverse impacts on the Company’s financial condition and results of operations. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, and the impact of any initiatives or programs that the Company may undertake to address financial and operational challenges faced by its customers. As of the date of issuance of these Condensed Consolidated and Combined Financial Statements, the extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity, or results of operations is uncertain. Accounting Standards Recently Adopted —In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-13, Fair Value Measurement (Topic 820), which modified the disclosures on fair value measurements by removing the requirement to disclose the amount and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and the policy for timing of such transfers. The ASU expands the disclosure requirements for Level 3 fair value measurements, primarily focused on changes in unrealized gains and losses included in other comprehensive income (loss). The Company adopted this guidance on January 1, 2020, which did not have a significant impact on the Company’s Condensed Consolidated and Combined Financial Statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment . This ASU simplified the test for goodwill impairment by removing Step 2 from the goodwill impairment test. Companies will now perform the goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount, recognizing an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value not to exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The Company adopted this guidance on January 1, 2020, which did not have a significant impact on the Company’s Condensed Consolidated and Combined Financial Statements. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which replaces the incurred loss methodology with an expected loss methodology that uses a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. The Company adopted this guidance on January 1, 2020, which did not have a significant impact on the Company’s Condensed Consolidated and Combined Financial Statements. Refer to Note 3 for additional disclosures required by Topic 326. Accounting Standards Not Yet Adopted —In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , which provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships and other transactions that reference London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform, if certain criteria are met. The ASU is effective for public entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments to eligible hedging relationships existing as of the beginning of the interim period that includes March 12, 2020 and to new eligible hedging relationships entered into after the beginning of the interim period that includes March 12, 2020. If an entity elects to apply any of the amendments for an eligible hedging relationship existing as of the beginning of the interim period that includes March 12, 2020, any adjustments as a result of those elections must be reflected as of the beginning of that interim period and recognized in accordance with the guidance in Reference Rate Reform Subtopics 848-30, 848-40, and 848-50 (as applicable). If an entity elects to apply any of the amendments for a new hedging relationship entered into between the beginning of the interim period that includes March 12, 2020 and March 12, 2020, any adjustments as a result of those elections must be reflected as of the beginning of the hedging relationship and recognized in accordance with the guidance in Reference Rate Reform Subtopics 848-30, 848-40, and 848-50 (as applicable). The expedients and exceptions provided by the amendments do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for hedging relationships existing as of December 31, 2022, that an entity has elected certain optional expedients for and that are retained through the end of the hedging relationship. The Company has not yet completed its assessment of the impact of the new standard on the Company’s Condensed Consolidated and Combined Financial Statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The ASU is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company has not yet completed its assessment of the impact of the new standard on the Company’s Condensed Consolidated and Combined Financial Statements. In August 2018, the FASB issued ASU No. 2018-14, Disclosure Framework — Changes to the Disclosure Requirements for Defined Benefit Plans , which amends Accounting Standards Codification (“ASC”) 715 to add, remove, and clarify disclosure requirements related to defined benefit pension plans. The ASU is effective for public entities for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company has not yet completed its assessment of the impact of the new standard on the Company’s Condensed Consolidated and Combined Financial Statements.

Acquisitions

Acquisitions	6 Months Ended
	Jul. 03, 2020
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into new and attractive business areas. The Company has completed a number of acquisitions that have been accounted for as business combinations and have resulted in the recognition of goodwill in the Company’s financial statements. Among other things, goodwill arises because the purchase prices for these businesses reflect a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations. The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains this information during due diligence and through other sources. In the months after closing, up to 12 months, as the Company obtains additional information that existed at the acquisition date about these assets and liabilities, it is able to refine the estimates of fair value and more accurately allocate the purchase price. Only items that existed as of the acquisition date are considered for subsequent adjustment. The Company will make appropriate adjustments to the purchase price allocation prior to completion of the measurement period, as required. On January 21, 2020, the Company acquired all of the shares of Matricel GmbH (“Matricel”) for cash consideration of approximately $44 million . Matricel, a German company, is a provider of biomaterials used in dental applications and complements the Company’s Specialty Products & Technologies segment. For the three and six months ended July 3, 2020, Matricel’s revenue and earnings were not material to the Condensed Consolidated and Combined Statement of Operations. During the three months ended July 3, 2020, the Company finalized the working capital adjustment and received $0.8 million , which was recorded as a reduction of goodwill. The Company is continuing to evaluate the deductibility of goodwill for income tax purposes. The following table summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date ($ in millions): January 21, 2020 Assets acquired: Cash $ 2.9 Trade accounts receivable 1.0 Inventories 1.9 Prepaid expenses and other current assets 0.2 Property, plant and equipment 0.5 Goodwill 24.4 Other intangible assets 22.3 Total assets acquired 53.2 Liabilities assumed: Trade accounts payable (0.1 ) Accrued expenses and other liabilities (9.4 ) Total liabilities assumed (9.5 ) Total net assets acquired $ 43.7 The excess of the purchase price over the fair value assigned to the assets acquired and liabilities assumed represents the goodwill resulting from the acquisition. Goodwill attributable to the acquisition has been recorded as a non-current asset and is not amortized, but is subject to review at least on an annual basis for impairment. Goodwill recognized was primarily attributable to expected operating efficiencies and expansion opportunities in the business acquired. The pro forma impact of this acquisition is not presented as it was not considered material to the Company's Condensed Consolidated and Combined Financial Statements. The intangible assets acquired consist of technology and customer relationships. The weighted average amortization period of the acquired intangible assets in the aggregate is 10 years.

Credit Losses

Credit Losses	6 Months Ended
	Jul. 03, 2020
Credit Loss [Abstract]
Credit Losses	CREDIT LOSSES The allowance for credits losses is a valuation account deducted from accounts receivable to present the net amount expected to be collected. Accounts receivable are charged off against the allowance when management believes the uncollectibility of an accounts receivable balance is confirmed. Management estimates the adequacy of the allowance by using relevant available information, from internal and external sources, relating to past events, current conditions and forecasts. Historical credit loss experience provides the basis for estimation of expected credit losses and is adjusted as necessary using the relevant information available. The allowance for credit losses is measured on a collective basis when similar risk characteristics exist. The Company has identified one portfolio segment based on the following risk characteristics: geographic regions, product lines, default rates and customer specific factors. The factors used by management in its credit loss analysis are inherently subject to uncertainty. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic, including the impact of delays in payments of outstanding receivable amounts beyond normal payment terms. If actual results are not consistent with management’s estimates and assumptions, the allowance for credit losses may be overstated or understated and a charge or credit to net income (loss) may be required. The rollforward of the allowance for credit losses is summarized as follows ($ in millions): Balance at December 31, 2019 $ 22.8 Foreign currency translation (0.7 ) Provision for credit losses 11.6 Write-offs charged against the allowance (3.1 ) Balance at July 3, 2020 $ 30.6

Inventories

Inventories	6 Months Ended
	Jul. 03, 2020
Inventory Disclosure [Abstract]
Inventories	INVENTORIES The classes of inventory are summarized as follows ($ in millions): July 3, 2020 December 31, 2019 Finished goods $ 230.3 $ 223.5 Work in process 38.3 36.5 Raw materials 90.3 89.9 Inventories, gross 358.9 349.9 Less: reserve for excess and obsolescence (78.1 ) (72.0 ) Inventories, net $ 280.8 $ 277.9

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jul. 03, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	PROPERTY, PLANT AND EQUIPMENT The classes of property, plant and equipment are summarized as follows ($ in millions): July 3, 2020 December 31, 2019 Land and improvements $ 23.8 $ 23.7 Buildings 173.1 166.9 Machinery and equipment 502.6 502.3 Property, plant and equipment, gross 699.5 692.9 Less: accumulated depreciation (405.2 ) (402.6 ) Property, plant and equipment, net $ 294.3 $ 290.3

Goodwill

Goodwill	6 Months Ended
	Jul. 03, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	GOODWILL The following is a rollforward of the Company’s goodwill ($ in millions): Specialty Products & Technologies Equipment & Consumables Total Balance at December 31, 2019 $ 2,008.1 $ 1,297.9 $ 3,306.0 Acquisitions 24.4 — 24.4 Foreign currency translation and other 3.0 0.4 3.4 Balance at July 3, 2020 $ 2,035.5 $ 1,298.3 $ 3,333.8 In addition to the annual impairment test, the Company is required to regularly assess whether a “triggering” event has occurred which would require interim impairment testing. Among other factors, the Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and its impact on each of the reporting units. Based on this assessment the Company did not identify any “triggering” events, which would indicate an impairment of goodwill is more likely than not as of July 3, 2020. The Company will continue to assess whether a “triggering” event has occurred which would require an interim impairment test and will perform an annual impairment test of goodwill during the fourth quarter. Determining the fair value of a reporting unit for purposes of the goodwill impairment test is judgmental in nature and involves the use of estimates and assumptions. These estimates and assumptions could have a significant impact on whether or not an impairment charge is recognized and also the magnitude of any such charge. Unforeseen negative changes in future business or other market conditions for any of our reporting units including margin compression or loss of business, could cause recorded goodwill to be impaired in the future.

Accrued Expenses And Other Liab

Accrued Expenses And Other Liabilities	6 Months Ended
	Jul. 03, 2020
Accrued expenses and other [Abstract]
Accrued Expenses and Other Liabilities	ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities were as follows ($ in millions): July 3, 2020 December 31, 2019 Current Noncurrent Current Noncurrent Compensation and benefits $ 111.8 $ 11.7 $ 151.2 $ 8.9 Employee severance and other benefits 37.3 0.5 5.6 — Pension benefits 8.5 89.9 8.5 89.4 Income and other taxes 12.5 283.2 39.3 254.0 Contract liabilities 43.1 3.9 52.6 4.4 Sales and product allowances 50.9 0.8 68.8 0.7 Loss contingencies 62.7 29.0 57.5 29.1 Other 92.6 21.9 87.1 12.8 Total $ 419.4 $ 440.9 $ 470.6 $ 399.3

Hedging Transactions And Deriva

Hedging Transactions And Derivative Financial Instruments	6 Months Ended
	Jul. 03, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Hedging Transactions and Derivative Financial Instruments	The Company uses cross-currency swap derivative contracts to partially hedge its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. On September 20, 2019, the Company entered into cross-currency swap derivative contracts with respect to its $650 million senior unsecured term loan facility. These contracts effectively convert the $650 million senior unsecured term loan facility to an obligation denominated in euros and partially offsets the impact of changes in currency rates on foreign currency denominated net investments. The changes in the fair value of these instruments are recorded in accumulated other comprehensive loss in equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive loss as reflected in Note 15. Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive loss into income during the period of change. The interest income or expense from these swaps is recorded in interest expense in the Company’s Condensed Consolidated and Combined Statements of Operations consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from September 2020 to September 2022. The Company also has foreign currency denominated long-term debt in the amount of €600.0 million . This senior unsecured term loan facility represents a partial hedge of the Company’s net investment in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro. The euro senior unsecured term loan facility is designated and qualifies as a non-derivative hedging instrument. Accordingly, the foreign currency translation of the euro senior unsecured term loan facility is recorded in accumulated other comprehensive loss in equity in the accompanying Condensed Consolidated Balance Sheets, offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive loss (see Note 15). Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive loss into income during the period of change. The euro senior unsecured term loan facility matures in September 2022. Refer to Note 13 for a further discussion of the above noted loan facilities. The Company uses interest rate swap derivative contracts to reduce its variability of cash flows related to interest payments with respect to its senior unsecured term loans. The interest rate swap contracts exchange interest payments based on variable rates for interest payments based on fixed rates. The changes in the fair value of these instruments are recorded in accumulated other comprehensive loss in equity (see Note 15). Any ineffective portions of the cash flow hedges are reclassified from accumulated other comprehensive loss into income during the period of change. The interest income or expense from these swaps is recorded in interest expense in the Company’s Condensed Consolidated and Combined Statements of Operations consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from September 2020 to September 2022. The following table summarizes the notional values as of July 3, 2020 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended July 3, 2020 ($ in millions): Notional Amount (Loss) Gain Recognized in OCI Three Months Ended July 3, 2020 Interest rate contracts $ 650.0 $ — Foreign currency contracts 650.0 (27.3 ) Foreign currency denominated debt 674.9 (26.2 ) Total $ 1,974.9 $ (53.5 ) Notional Amount (Loss) Gain Recognized in OCI Six Months Ended July 3, 2020 Interest rate contracts $ 650.0 $ (11.7 ) Foreign currency contracts 650.0 9.7 Foreign currency denominated debt 674.9 (2.0 ) Total $ 1,974.9 $ (4.0 ) The Company did not reclassify any deferred gains or losses related to net investment and cash flow hedges from accumulated other comprehensive loss to income during the three and six months ended July 3, 2020. In addition, the Company did not have any ineffectiveness related to net investment and cash flow hedges during the three and six months ended July 3, 2020. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in investing activities in the accompanying Condensed Consolidated and Combined Statements of Cash Flows. The Company did not have any such derivatives during the three and six months ended June 28, 2019. The Company’s derivative instruments, as well as its non-derivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Condensed Consolidated Balance Sheets as follows ($ in millions): July 3, 2020 December 31, 2019 Derivative assets: Prepaid expenses and other current assets $ — $ 0.1 Other long-term assets $ 3.3 $ — Derivative liabilities: Accrued expense and other liabilities $ 3.2 $ 8.9 Other long-term liabilities $ 10.9 $ — Non-derivative hedging instruments: Long-term debt $ 674.9 $ 672.9

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jul. 03, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation; and Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety. A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Quoted Prices in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total July 3, 2020: Assets: Cross-currency swap derivative contracts $ — $ 3.3 $ — $ 3.3 Liabilities: Cross-currency swap derivative contracts $ — $ 2.5 $ — $ 2.5 Interest rate swap derivative contracts $ — $ 11.6 $ — $ 11.6 Deferred compensation plans $ — $ 9.4 $ — $ 9.4 December 31, 2019: Assets: Interest rate swap derivative contracts $ — $ 0.1 $ — $ 0.1 Liabilities: Cross-currency swap derivative contracts $ — $ 8.9 $ — $ 8.9 Deferred compensation plans $ — $ 7.2 $ — $ 7.2 Derivative Instruments The cross-currency swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and foreign currency current exchange rates and forward curves as inputs. The interest rate swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and forward curves as inputs. Refer to Note 8 for additional information. Deferred Compensation Plans Certain management employees of the Company participate in nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis. All amounts deferred under this plan are unfunded, unsecured obligations and are presented as a component of the Company’s compensation and benefits accrual included in accrued expenses in the accompanying Condensed Consolidated Balance Sheets (refer to Note 7). Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within the Company’s 401(k) program. Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates on investment options within the Company’s 401(k) program. Amounts voluntarily deferred by employees into the Company stock fund and amounts contributed to participant accounts by the Company are deemed invested in the Company’s common stock and future distributions of such contributions will be made solely in shares of Company common stock, and therefore are not reflected in the above amounts. Fair Value of Financial Instruments The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions): July 3, 2020 December 31, 2019 Carrying Amount Fair Value Carrying Amount Fair Value Assets: Cross-currency swap derivative contracts $ 3.3 $ 3.3 $ — $ — Interest rate swap derivative contracts $ — $ — $ 0.1 $ 0.1 Liabilities: Cross-currency swap derivative contracts $ 2.5 $ 2.5 $ 8.9 $ 8.9 Interest rate swap derivative contracts $ 11.6 $ 11.6 $ — $ — Long-term debt, excluding convertible senior notes due 2025 $ 1,321.0 $ 1,321.0 $ 1,321.0 $ 1,321.0 Convertible senior notes due 2025 $ 401.2 $ 644.2 $ — $ —

Pension And Other Benefit Plans

Pension And Other Benefit Plans	6 Months Ended
	Jul. 03, 2020
Retirement Benefits [Abstract]
Pension and Other Benefit Plans	PENSION AND OTHER BENEFIT PLANS The following sets forth the components of the Company’s net periodic benefit costs of the defined benefit pension plans ($ in millions): Components of net periodic pension cost: Three Month Period Ended Six Month Period Ended ($ in millions) July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Service cost $ (2.6 ) $ (2.3 ) $ (5.2 ) $ (4.6 ) Interest cost (0.4 ) (0.6 ) (0.8 ) (1.1 ) Expected return on plan assets 0.9 0.8 1.8 1.6 Amortization of initial net obligation (0.1 ) — (0.2 ) (0.1 ) Amortization of prior service credit 0.1 — 0.2 — Amortization of actuarial loss (0.4 ) (0.1 ) (0.8 ) (0.2 ) Curtailment and settlement gains recognized — 1.2 — 1.2 Net periodic pension cost $ (2.5 ) $ (1.0 ) $ (5.0 ) $ (3.2 ) The net periodic benefit costs are reflected in the following captions in the accompanying Condensed Consolidated and Combined Statements of Operations ($ in millions): Three Month Period Ended Six Month Period Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Service cost: Selling, general and administrative expenses $ (2.6 ) $ (2.3 ) $ (5.2 ) $ (4.6 ) Other net periodic pension costs: Nonoperating income (expense), net 0.1 1.3 0.2 1.4 Total $ (2.5 ) $ (1.0 ) $ (5.0 ) $ (3.2 )

Warranty

Warranty	6 Months Ended
	Jul. 03, 2020
Commitments and Contingencies Disclosure [Abstract]
Warranty	WARRANTY The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly and appropriately maintained. Warranty periods depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain instances estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. The following is a rollforward of the Company’s accrued warranty liability ($ in millions): Balance at December 31, 2019 $ 9.6 Accruals for warranties issued during the year 7.4 Payments made (7.3 ) Effect of foreign currency translation (0.1 ) Balance at July 3, 2020 $ 9.6

Litigation And Contingencies

Litigation And Contingencies	6 Months Ended
	Jul. 03, 2020
Commitments and Contingencies Disclosure [Abstract]
Litigation And Contingencies	LITIGATION AND CONTINGENCIES For a description of the Company’s litigation and contingencies, refer to Note 12 of the Company’s Consolidated and Combined Financial Statements as of and for the year ended December 31, 2019, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. The Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated and has accrued $92 million and $87 million as of July 3, 2020 and December 31, 2019, respectively, which are included in accrued liabilities in the condensed consolidated balance sheets. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period. On October 6, 2015, Professor Nitzan Bichacho, Dr. Ophir Fromovich, Dr. Ben-Zion Karmon and Dr. Yuval Yaacoby (collectively, “Claimants”) initiated arbitration against Nobel Biocare Services AG (“Nobel”) in the International Court of Arbitration of the International Chamber of Commerce in Zurich, Switzerland, seeking damages for alleged breaches by Nobel of a 2005 patent transfer and consultancy agreement between the parties and Nobel’s alleged underpayment of royalties related thereto. Claimants’ Request for Arbitration alleged damages of $30 million and Claimants have presented arguments that suggest that they are, in fact, seeking damages in excess of that amount. The Company has recognized a loss reserve for its best estimate in the range of probable damages related to this matter, which is included within the Company’s accrual for legal matters described above.

Debt and Credit Facilities

Debt and Credit Facilities	6 Months Ended
	Jul. 03, 2020
Debt Disclosure [Abstract]
Debt and Credit Facilities	DEBT AND CREDIT FACILITIES The components of the Company’s debt were as follows ($ in millions): July 3, 2020 December 31, 2019 Senior term loan facility due 2022 ($650.0 million aggregate principal amount) (the “Term Loan Facility”), net of deferred debt issuance costs of $2.3 million and $1.3 million, respectively $ 647.7 $ 648.7 Senior euro term loan facility due 2022 (€600.0 million aggregate principal amount) (the “Euro Term Loan Facility”), net of deferred debt issuance costs of $1.7 million and $0.9 million, respectively 673.2 672.0 Senior multi-currency revolving credit facility ($250.0 million borrowing capacity) (the “Revolving Credit Facility”) 249.8 — Convertible senior notes, net of deferred debt issuance costs of $11.7 million and unamortized discount of $104.6 million 401.2 — Other 3.8 4.2 Total debt 1,975.7 1,324.9 Less: current portion (253.5 ) (3.9 ) Long-term debt $ 1,722.2 $ 1,321.0 Unamortized debt issuance costs and discount totaled $120 million as of July 3, 2020, which have been netted against their respective aggregate principal amounts of the related debt in the table above and are being amortized to interest expense over the term of the respective debt. Long-Term Indebtedness 2019 Credit Agreement On September 20, 2019, the Company entered into a credit agreement (the “Credit Agreement”) with a syndicate of banks under which Envista borrowed approximately $1.3 billion , consisting of the three-year $650 million Term Loan Facility and the three-year €600 million Euro Term Loan Facility (together with the Term Loan Facility, the “Term Loans”). The Credit Agreement also includes the five-year, $250 million Revolving Credit Facility (together with the Term Loans, the “Senior Credit Facilities”). Pursuant to the Separation Agreement, all of the net proceeds of the Term Loans were paid to Danaher as partial consideration for the Dental business Danaher transferred to Envista, as further discussed in Note 1 . The Revolving Credit Facility includes an initial aggregate principal amount of $250 million with a $20 million sublimit for the issuance of standby letters of credit. The Company has the option to increase the amount available under the Revolving Credit Facility, subject to agreement by the lenders, by up to an additional $200 million in the aggregate. The Revolving Credit Facility can be used for working capital and other general corporate purposes. As of July 3, 2020, the Revolving Credit Facility has been fully drawn down. This amount is classified as current as of July 3, 2020 as the Company expects that it will be repaid within the next twelve months. The interest rates for borrowings under the Term Loan Facility, Euro Term Loan Facility and Revolving Credit Facility were 3.7% , 2.5% and 3.1% , respectively, for the three months ended July 3, 2020 and 3.4% , 1.8% and 3.0% , respectively, for the six months ended July 3, 2020. The Company has entered into interest rate swap derivative contracts for the Term Loan Facility, as further discussed in Note 8. On May 6, 2020, the Company entered into an amendment to its Credit Agreement (the “Amendment”) that, among other changes, waives the quarterly-tested leverage covenant and reduces the interest coverage ratio through and including the first quarter of 2021. In connection with this Amendment, the lenders obtained a first priority security interest in substantially all of the Company’s assets. The Amendment also imposes limitations on liens, indebtedness, asset sales, investments and acquisitions. In addition, the Company will be required to maintain a monthly-tested minimum liquidity covenant during the waiver period. The Amendment increases the interest and fees payable under the Credit Agreement for the duration of the period during which the waiver of the debt covenants remains in effect. Substantially all terms of the Credit Agreement revert back to the original terms as soon as the Company submits a quarterly compliance certificate with debt covenants at pre-Amendment levels. The Company incurred fees aggregating $3 million in connection with this Amendment, of which $2 million were deferred and will be amortized to interest expense over the term of the debt and the remaining amount was expensed. The Credit Agreement also contains customary events of default. Upon the occurrence and during the continuance of an event of default, the lenders may declare the outstanding advances and all other obligations under the Credit Agreement immediately due and payable. The Company was in compliance with the interest coverage ratio and other applicable covenants as of July 3, 2020. Convertible Senior Notes (the “Notes”) On May 21, 2020, the Company issued the Notes due on June 1, 2025, unless earlier repurchased, redeemed or converted. The aggregate principal amount, which includes the initial purchasers’ exercise in full of their option to purchase an additional $68 million principal amount of the Notes, was $518 million . The net proceeds from the issuance, after deducting purchasers’ discounts and estimated offering expenses, were $503 million . The Company used part of the net proceeds to pay for the capped call transactions (“Capped Calls”) as further described below. The Notes will accrue interest at a rate of 2.375% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020. The Notes have an initial conversion rate of 47.5862 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $21.01 per share of the Company’s common stock and is subject to adjustment upon the occurrence of specified events. The Notes are governed by an indenture dated as of May 21, 2020 (the “Indenture”) between the Company and Wilmington Trust, National Association, as trustee. The Indenture does not contain any financial covenants or any restrictions on the payment of dividends, the incurrence of senior debt or other indebtedness or the issuance or repurchase of the Company’s securities by the Company. The Notes are the Company’s senior, unsecured obligations and are (i) equal in right of payment with our existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Holders of the Notes may convert their Notes at any time on or after December 2, 2024 until the close of business on the second scheduled trading day preceding the maturity date. Holders of the Notes will also have the right to convert the Notes prior to December 2, 2024, but only upon the occurrence of specified events. Upon conversion, the Notes will be settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. The Company’s current intent and policy is to settle all Notes conversions through combination settlement, satisfying the principal amount outstanding with cash and any Notes conversion value in excess of the principal amount in shares of the Company’s common stock. If a fundamental change occurs prior to the maturity date, holders of the Notes may require the Company to repurchase all or a portion of their Notes for cash at a repurchase price equal to 100% of the principal amount plus any accrued and unpaid interest. In addition, if specific corporate events occur prior to the maturity date, the Company would increase the conversion rate for a holder who elects to convert its Notes in connection with such an event in certain circumstances. As of July 3, 2020, none of the conditions permitting early conversion by holders of the Notes had been met, therefore, the Notes are classified as long-term. The Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 1, 2023 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding the redemption date, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption. In accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components of $411 million and $107 million , respectively. The carrying amount of the liability component was calculated by measuring the fair value of a similar debt instrument that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Notes. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the liability component over its carrying amount (“debt discount”) will be amortized to interest expense over the term of the Notes. The Company allocated the total issuance costs incurred to the liability and equity components of the Notes based on their relative values. Issuance costs attributable to the liability component of $12 million were recorded as a reduction to the liability portion of the Notes and will be amortized as interest expense over the term of the Notes. The issuance costs of $3 million attributable to the equity component were netted with the equity component in stockholders’ equity. The Company recorded a net deferred tax liability of $20 million in connection with the issuance of the Notes, which was recorded to stockholders’ equity. The following table sets forth total interest expense recognized related to the Notes ($ in millions): Three and Six Months Ended July 3, 2020 Contractual interest expense $ 1.4 Amortization of debt issuance costs 0.2 Amortization of debt discount 2.0 Total interest expense $ 3.6 For the three and six months ended July 3, 2020, the debt discount and debt issuance costs were amortized using an annual effective interest rate of 7.3% to interest expense over the term of the Notes. As of July 3, 2020, the fair value of the Notes was $644 million . The fair value was determined based on the quoted bid price of the Notes in an over-the-counter market on July 3, 2020. The Notes are considered as Level 2 of the fair value hierarchy. As of July 3, 2020, the if-converted value of the Notes exceeds the outstanding principal amount by $9 million . Capped Call Transactions In connection with the offering of the Notes, the Company entered into Capped Calls with certain counterparties. The Capped Calls each have an initial strike price of approximately $21.01 per share, subject to certain adjustments, which corresponds to the initial conversion price of the Notes. The Capped Calls have initial cap prices of $23.79 per share, subject to certain adjustments. The Capped Calls cover, subject to anti-dilution adjustments, 2.9 million shares of the Company's common stock. The Capped Calls are generally intended to reduce or offset the potential dilution from shares of common stock issued upon any conversion of the Notes with such reduction or offset, as the case may be, subject to a cap based on the cap price. As the Capped Call transactions are considered indexed to the Company's own stock and are considered equity classified, they are recorded in equity and are not accounted for as derivatives. The cost of $21 million incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital.

Stock Transactions

Stock Transactions	6 Months Ended
	Jul. 03, 2020
Share-based Payment Arrangement [Abstract]
Stock Transactions	STOCK TRANSACTIONS Capital Stock Under the Company’s amended and restated certificate of incorporation, as of September 20, 2019, the Company’s authorized capital stock consists of 500 million shares of common stock with a par value of $0.01 per share and 15 million shares of preferred stock with no par value per share. On September 17, 2019, the Company issued shares of the Company’s common stock to Danaher as partial consideration for the transfer of the Dental business by Danaher to the Company, which, together with the 100 shares of the Company’s common stock previously held by Danaher resulted in Danaher owning 127.9 million shares of the Company’s common stock. On September 20, 2019, the Company completed its IPO resulting in the issuance of an additional 30.8 million shares of its common stock. No preferred shares were issued or outstanding as of July 3, 2020. Each share of the Company’s common stock entitles the holder to one

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jul. 03, 2020
Equity [Abstract]
Accumulated Other Comprehensive Loss	ACCUMULATED OTHER COMPREHENSIVE LOSS The changes in accumulated other comprehensive loss by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended July 3, 2020 Balance at April 3, 2020 $ (153.6 ) $ (8.8 ) $ (27.5 ) $ (189.9 ) Other comprehensive income before reclassifications: Increase 19.9 — — 19.9 Income tax impact 13.2 — — 13.2 Other comprehensive income before reclassifications, net of income taxes 33.1 — — 33.1 Amounts reclassified from accumulated other comprehensive loss: Increase — — 0.3 0.3 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — 0.3 0.3 Net current period other comprehensive income, net of income taxes 33.1 — 0.3 33.4 Balance at July 3, 2020 $ (120.5 ) $ (8.8 ) $ (27.2 ) $ (156.5 ) Foreign Currency Translation Adjustments Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended June 28, 2019 Balance at March 29, 2019 $ (112.1 ) $ — $ (3.8 ) $ (115.9 ) Other comprehensive income before reclassifications: Increase 31.2 — — 31.2 Other comprehensive loss before reclassifications, net of income taxes 31.2 — — 31.2 Amounts reclassified from accumulated other comprehensive loss: Decrease — — (1.1 ) (1.1 ) Income tax impact — — 0.4 0.4 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.7 ) (0.7 ) Net current period other comprehensive income (loss), net of income taxes 31.2 — (0.7 ) 30.5 Balance at June 28, 2019 $ (80.9 ) $ — $ (4.5 ) $ (85.4 ) Foreign Currency Translation Adjustments Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended July 3, 2020 Balance at December 31, 2019 $ (116.4 ) $ 0.1 $ (27.9 ) $ (144.2 ) Other comprehensive loss before reclassifications: Decrease (2.2 ) (11.7 ) — (13.9 ) Income tax impact (1.9 ) 2.8 — 0.9 Other comprehensive loss before reclassifications, net of income taxes (4.1 ) (8.9 ) — (13.0 ) Amounts reclassified from accumulated other comprehensive loss: Increase — — 0.8 0.8 Income tax impact — — (0.1 ) (0.1 ) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — 0.7 0.7 Net current period other comprehensive (loss) income, net of income taxes (4.1 ) (8.9 ) 0.7 (12.3 ) Balance at July 3, 2020 $ (120.5 ) $ (8.8 ) $ (27.2 ) $ (156.5 ) Foreign Currency Translation Adjustments Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended June 28, 2019 Balance at December 31, 2018 $ (74.3 ) $ — $ (3.9 ) $ (78.2 ) Other comprehensive loss before reclassifications: Decrease (6.6 ) — — (6.6 ) Other comprehensive loss before reclassifications, net of income taxes (6.6 ) — — (6.6 ) Amounts reclassified from accumulated other comprehensive loss: Decrease — — (0.9 ) (a) (0.9 ) Income tax impact — — 0.3 0.3 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.6 ) (0.6 ) Net current period other comprehensive loss, net of income taxes (6.6 ) — (0.6 ) (7.2 ) Balance at June 28, 2019 $ (80.9 ) $ — $ (4.5 ) $ (85.4 )

Revenue

Revenue	6 Months Ended
	Jul. 03, 2020
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE The following tables present the Company’s revenues disaggregated by geographical region for the three and six months ended July 3, 2020 and June 28, 2019 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenues. The Company has historically defined emerging markets as developing markets of the world, which prior to the COVID-19 pandemic, have experienced extended periods of accelerated growth in gross domestic product and infrastructure, which includes Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not emerging markets. Specialty Products & Technologies Equipment & Consumables Total Three Months Ended July 3, 2020 Geographical region: North America $ 77.9 $ 84.2 $ 162.1 Western Europe 41.0 32.8 73.8 Other developed markets 15.8 12.2 28.0 Emerging markets 49.9 48.2 98.1 Total $ 184.6 $ 177.4 $ 362.0 Three Months Ended June 28, 2019 Geographical region: North America $ 152.3 $ 187.9 $ 340.2 Western Europe 83.2 72.9 $ 156.1 Other developed markets 24.0 21.0 $ 45.0 Emerging markets 87.8 83.0 170.8 Total $ 347.3 $ 364.8 $ 712.1 Specialty Products & Technologies Equipment & Consumables Total Six Months Ended July 3, 2020 Geographical region: North America $ 206.2 $ 225.6 $ 431.8 Western Europe 103.7 90.7 194.4 Other developed markets 37.0 28.7 65.7 Emerging markets 110.3 107.0 217.3 Total $ 457.2 $ 452.0 $ 909.2 Six Months Ended June 28, 2019 Geographical region: North America $ 301.9 $ 336.8 $ 638.7 Western Europe 172.6 143.6 $ 316.2 Other developed markets 46.8 38.6 $ 85.4 Emerging markets 174.8 156.7 331.5 Total $ 696.1 $ 675.7 $ 1,371.8 Sales by major product group ($ in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Consumables $ 255.3 $ 492.8 $ 633.2 $ 953.6 Equipment 106.7 219.3 276.0 418.2 Total $ 362.0 $ 712.1 $ 909.2 $ 1,371.8 Remaining Performance Obligations ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) requires disclosure of remaining performance obligations that represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include noncancelable purchase orders, extended warranty and service agreements and do not include revenue from contracts with customers with an original term of one year or less. As of July 3, 2020, the aggregate amount of the transaction price allocated to remaining performance obligations was $18 million and the Company expects to recognize revenue on the majority of this amount over the next 12 months . Contract Liabilities The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Condensed Consolidated Balance Sheets based on the timing of when the Company expects to recognize revenue. As of July 3, 2020, and December 31, 2019, the contract liabilities were $47 million and $57 million , respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. Revenue recognized during the six months ended July 3, 2020 and June 28, 2019 that was included in the contract liability balance on December 31, 2019 and December 31, 2018, was $32 million and $39 million , respectively. Significant Customers No individual customer accounted for more than 10% of sales in the three and six months ended July 3, 2020. Sales to the Company’s largest customer were 13% and 12% of sales in the three and six months ended June 28, 2019, respectively. Seasonality Based on historical experience, the Company generally has more sales in the second half of the calendar year than in the first half of the calendar year, with the first quarter typically having the lowest sales of the year. Based on historical customer buying patterns, the Company generally has more sales in the fourth quarter than in any other quarter of the year, driven in particular by capital spending in the Equipment & Consumables segment. As a result of this seasonality in sales, profitability in the Equipment & Consumables segment also tends to be higher in the second half of the year. There are no assurances that these historical trends will continue in the future.

Restructuring Activities

Restructuring Activities	6 Months Ended
	Jul. 03, 2020
Restructuring and Related Activities [Abstract]
Restructuring Activities	RESTRUCTURING ACTIVITIES The Company’s restructuring activities are undertaken as necessary to implement management’s strategy, streamline operations, take advantage of available capacity and resources, and ultimately achieve net cost reductions. These activities generally relate to the realignment of existing manufacturing capacity and closure of facilities and other exit or disposal activities, as it relates to executing the Company’s strategy, either in the normal course of business or pursuant to significant restructuring programs. As of the end of the second quarter, the Company was unable to reasonably estimate an obligation for any future employee severance and other benefits related to the Company’s restructuring activities. The Company initiated restructuring related activities during the six months ended July 3, 2020. The related liability, which is included in accrued liabilities in the Condensed Consolidated Balance Sheets, is summarized below ($ in millions): Employee Severance Facility Exit Total Balance at December 31, 2019 $ 5.6 $ — $ 5.6 Costs incurred 45.6 7.3 52.9 Paid/settled (15.5 ) (5.2 ) (20.7 ) Balance at July 3, 2020 $ 35.7 $ 2.1 $ 37.8 During the three months ended July 3, 2020, the Company made the decision to exit a portion of its treatment unit business, which is part of the Equipment & Consumables segment, as part of its strategy to restructure its portfolio and improve its cost structure. In connection with the planned exit, which is expected to be substantially complete by the end of the third quarter, the Company recognized a non-cash loss of $19 million . The majority of this loss included $9 million related to the impairment of certain intangible assets, which is included in selling, general and administrative expenses and $9 million of inventory write-offs, which is included in cost of sales. As soon as the production activities are completed, the Company expects to sell the manufacturing facility related to this business. Restructuring related charges recorded for the three and six months ended July 3, 2020 and June 28, 2019, by segment were as follows ($ in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Specialty Products & Technologies $ 15.7 $ 3.5 $ 16.5 $ 3.2 Equipment & Consumables 41.2 1.3 52.0 3.6 Other 3.0 — 3.7 — Total $ 59.9 $ 4.8 $ 72.2 $ 6.8 The restructuring related charges incurred during the three and six months ended July 3, 2020 and June 28, 2019, are reflected in the following captions in the accompanying Condensed Consolidated and Combined Statements of Operations ($ in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Cost of sales $ 23.9 $ 0.9 $ 26.7 $ 1.8 Selling, general and administrative expenses 36.0 3.9 45.5 5.0 Total $ 59.9 $ 4.8 $ 72.2 $ 6.8

Income Taxes

Income Taxes	6 Months Ended
	Jul. 03, 2020
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES Prior to the Split-Off, the Company’s operating results were included in Danaher’s various consolidated U.S. federal and certain state income tax returns, as well as certain non-U.S. returns. For periods prior to the Split-Off, the Company’s Condensed Consolidated and Combined Financial Statements reflect income tax expense and deferred tax balances as if the Company had filed tax returns on a standalone basis separate from Danaher. The separate return method applies the accounting guidance for income taxes to the standalone financial statements as if the Company was a separate taxpayer and a standalone enterprise for periods prior to the Split-Off. The Company’s effective tax rate of 23.5% and 20.3% for the three months ended July 3, 2020 and June 28, 2019, respectively, and effective tax rate of 26.4% and 18.7% for the six months ended July 3, 2020 and June 28, 2019, respectively, differ from the U.S. federal statutory rate of 21.0%, primarily due to the Company’s geographical mix of earnings as a result of the impact of COVID-19 in the three and six months ended July 3, 2020. On March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The CARES Act is an emergency economic stimulus package in response to the COVID-19 outbreak which, among other things, contains numerous income tax provisions. Some of these tax provisions are expected to be effective retroactively for years ending before the date of enactment. The Company has not identified material impacts to the quarterly provision as of and for the three and six months ended July 3, 2020 and does not anticipate that the provisions of the CARES Act will impact income taxes in 2020. The Company will continue to evaluate the impact of the CARES Act as new clarifying guidance is issued throughout 2020.

(Loss) Earnings Per Share

(Loss) Earnings Per Share	6 Months Ended
	Jul. 03, 2020
Earnings Per Share [Abstract]
(Loss) Earnings Per Share	(LOSS) EARNINGS PER SHARE Basic (loss) earnings per share is calculated by dividing net (loss) income by the weighted average number of shares of common stock outstanding for the applicable period. Diluted earnings per share is computed based on the weighted average number of common shares outstanding plus the effect of dilutive potential shares outstanding during the period using the treasury stock method. Dilutive potential common shares include employee equity options, non-vested shares and similar instruments granted by the Company and the assumed conversion impact of the Notes. The Company’s current intent and policy is to settle all Notes conversions through a combination settlement by satisfying the principal amount outstanding with cash and any Notes conversion value in excess of the principal amount in shares of the Company’s common stock. As such, the Company uses the treasury stock method for the assumed conversion of the Notes to compute the weighted average shares of common stock outstanding for diluted earnings per share. As the Company intends and has the ability to settle the principal amount of the Notes in cash upon conversion, the Notes will not have an impact on the Company's diluted earnings per share until the average share price of the Company’s common stock exceeds the conversion price of $21.01 per share. In connection with the offering of the Notes, the Company entered into Capped Calls (see further discussion in Note 13), which are intended to reduce or offset the potential dilution from shares of common stock issued upon conversion of the Notes. However, this impact is not included when calculating potentially dilutive shares since their effect is anti-dilutive. Until the average market price of the Company's common stock exceeds the cap price of $23.79 per share, exercise of the Capped Calls will mitigate dilution from the Notes. The Company’s issuance of shares of its common stock to Danaher as partial consideration for the transfer of the Dental business by Danaher to the Company on September 17, 2019, together with the 100 shares of the Company’s common stock previously held by Danaher, resulted in 127.9 million shares of the Company’s common stock being held by Danaher, which are being utilized for the calculation of both basic and diluted earnings per share for the three and six months ended June 28, 2019. In connection with the IPO, an additional 30.8 million shares were issued on September 20, 2019. For periods prior to the Separation, the Company’s stock-based compensation expense includes expense for Danaher equity awards granted to certain of the Company’s employees. As these equity awards related to Danaher common stock, rather than common stock of the Company, the calculation of diluted earnings per share does not include the potential dilutive impact of these equity awards for periods prior to the Split-Off. At the time of the Split-Off, the equity awards held by certain employees to purchase Danaher shares were converted into equity awards to purchase the Company’s shares and the converted equity awards are included in the Company’s calculation of diluted earnings per share in periods where the Company has net income. The table below presents the computation of basic and diluted (loss) earnings per share (in millions, except per share amounts): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Numerator: Net (loss) income $ (93.5 ) $ 61.5 $ (110.7 ) $ 99.4 Denominator: Weighted-average common shares outstanding used in basic and diluted (loss) earnings per share 159.5 127.9 159.3 127.9 (Loss) earnings per share: Basic and diluted $ (0.59 ) $ 0.48 $ (0.69 ) $ 0.78 Since the Company was in a net loss position for the three and six months ended July 3, 2020, no shares reserved for issuance upon exercise of stock options, vesting of restricted stock units or assumed conversion of the Notes were included in the computation of diluted loss per share as their inclusion would have been anti-dilutive . The Notes did not have an impact on the Company’s diluted share count as the average stock price of the Company’s common stock did not exceed $21.01 . The following table presents outstanding securities not included in the computation of diluted (loss) income per share, because their effect was anti-dilutive (in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Stock-based awards 8.4 — 7.1 —

Segment Information

Segment Information	6 Months Ended
	Jul. 03, 2020
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company operates and reports its results in two separate business segments, the Specialty Products & Technologies and Equipment & Consumables segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income (expense) and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. The identifiable assets by segment are those used in each segment’s operations. Inter-segment amounts are not significant and are eliminated to arrive at consolidated totals. The Company’s Specialty Products & Technologies products include implants, prosthetics, orthodontic brackets, aligners and lab products. The Company’s Equipment & Consumables products include traditional consumables such as bonding agents and cements, impression materials, infection prevention products and restorative products, while the Company’s equipment products include treatment units, instruments, digital imaging systems, software and other visualization and magnification systems. Segment related information is shown below ($ in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Sales: Specialty Products & Technologies $ 184.6 $ 347.3 $ 457.2 $ 696.1 Equipment & Consumables 177.4 364.8 452.0 675.7 Total $ 362.0 $ 712.1 $ 909.2 $ 1,371.8 Operating (loss) profit and reconciliation to (loss) income before income taxes: Specialty Products & Technologies $ (19.2 ) $ 54.5 $ (11.4 ) $ 120.6 Equipment & Consumables (53.8 ) 29.2 (73.1 ) 17.0 Other (34.9 ) (7.8 ) (48.4 ) (16.8 ) Operating (loss) profit (107.9 ) 75.9 (132.9 ) 120.8 Nonoperating income (expense): Other income 0.1 1.3 0.2 1.4 Interest expense, net (14.5 ) — (17.8 ) — (Loss) income before income taxes $ (122.3 ) $ 77.2 $ (150.5 ) $ 122.2 July 3, 2020 December 31, 2019 Identifiable assets: Specialty Products & Technologies $ 3,693.5 $ 3,662.5 Equipment & Consumables 2,118.1 2,256.6 Other 853.6 239.2 Total $ 6,665.2 $ 6,158.3

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jul. 03, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	RELATED-PARTY TRANSACTIONS In connection with the Separation, the Company entered into various agreements with Danaher, including but not limited to, a Separation Agreement, a Transition Services Agreement, a Tax Matters Agreement, an Employee Matters Agreement, an Intellectual Property Matters Agreement and a Danaher Business System (“DBS”) License Agreement, which set forth certain terms and conditions related to transactions which will continue between Danaher and the Company post-Separation. Separation Agreement The Separation Agreement governs the Separation and provides a framework for the relationship between the parties going forward. Transition Services Agreement The Transition Services Agreement sets forth the terms and conditions pursuant to which the Company and its subsidiaries and Danaher and its subsidiaries will provide to each other various services after the Separation. The services to be provided include information technology, facilities, certain accounting and other financial functions, and administrative services. The charges for the transition services generally are expected to allow the providing company to fully recover all out-of-pocket costs and expenses it actually incurs in connection with providing the service, plus, in some cases, the allocated indirect costs of providing the services, generally without profit. Tax Matters Agreement The Tax Matters Agreement governs the respective rights, responsibilities and obligations of both the Company and Danaher after the Separation with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. Employee Matters Agreement The Employee Matters Agreement sets forth, among other things, the allocation of assets, liabilities and responsibilities relating to employee compensation and benefit plans and programs and other related matters in connection with the Separation, including the treatment of outstanding equity and other incentive awards and certain retirement and welfare benefit obligations. Intellectual Property Matters Agreement The Intellectual Property Matters Agreement sets forth the terms and conditions pursuant to which Danaher and the Company have mutually granted certain personal, generally irrevocable, non-exclusive, worldwide, and royalty-free rights to use certain intellectual property. Both parties are able to sublicense their rights in connection with activities relating to their businesses, but not for independent use by third parties. DBS License Agreement The DBS License Agreement sets forth the terms and conditions pursuant to which Danaher has granted a non-exclusive, worldwide, non-transferable, perpetual license to us to use DBS solely in support of our businesses. The Company is able to sublicense such license solely to direct and indirect wholly-owned subsidiaries. In addition, both parties have licensed to each other improvements made by such party to DBS during the first two years of the term of the DBS license agreement. The Company has historically operated as part of Danaher and not as a separate, publicly-traded company. Accordingly, Danaher has allocated certain shared costs to the Company that are reflected as expenses in these Condensed Consolidated and Combined Financial Statements for the periods prior to Separation. Management considers the allocation methodologies used by Danaher to be reasonable and to appropriately reflect the related expenses attributable to the Company for purposes of the Condensed Consolidated and Combined Financial Statements; however, the expenses reflected in these financial statements may not be indicative of the actual expenses that would have been incurred during the periods presented if the Company had operated as a separate entity. In addition, the expenses reflected in the financial statements may not be indicative of expenses the Company will incur in the future. Following the Split-Off, Danaher no longer owns any of the Company’s outstanding common stock and is no longer a related party and the Company no longer considers transactions with Danaher as related party transactions. Corporate Expenses Certain corporate overhead and shared expenses incurred by Danaher and its subsidiaries have been allocated to the Company and are reflected in the Condensed Consolidated and Combined Statements of Operations. These amounts included, but were not limited to, items such as general management and executive oversight, costs to support Danaher information technology infrastructure, facilities, compliance, human resources and legal functions and financial management and transaction processing including public company reporting, consolidated tax filings and tax planning, Danaher benefit plan administration, risk management and consolidated treasury services, certain employee benefits and incentives and stock based compensation administration. These costs were allocated using methodologies that management believes are reasonable for the item being allocated. Allocation methodologies included the Company’s relative share of revenues, headcount or functional spend as a percentage of the total. Insurance Programs Administered by Former Parent In addition to the corporate allocations discussed above, the Company was allocated expenses related to certain insurance programs Danaher administered on behalf of the Company, including workers’ compensation, property, cargo, automobile, crime, fiduciary, product, general and directors’ and officers’ liability insurance. The insurance costs of these policies were allocated by Danaher to the Company using various methodologies related to the respective, underlying exposure base. For the self-insured component of the policies referenced above, Danaher allocated costs to the Company based on the Company’s incurred claims. Medical Insurance Programs Administered by Former Parent In addition to the corporate allocations noted above, the Company was allocated expenses related to the medical insurance programs Danaher administered on behalf of the Company. These amounts were allocated using actual medical claims incurred during the period for the associated employees attributable to the Company. In connection with the Separation, the Company established independent medical insurance programs similar to those previously provided by Danaher. Deferred Compensation Program Administered by Former Parent Certain of the Company’s management employees participated in Danaher’s nonqualified deferred compensation programs that permit participants to defer a portion of their compensation, on a pretax basis prior to the Separation. All amounts deferred under this plan are unfunded, unsecured obligations of Danaher and subject to reimbursement by the Company. In connection with the Separation, the Company established a similar independent, nonqualified deferred compensation program. After the Separation there were no related-party expenses allocated to the Company. The amounts of related-party expenses allocated to the Company from Danaher for the three and six months ended June 28, 2019, were as follows ($ in millions): Three Months Ended Six Months Ended June 28, 2019 June 28, 2019 Allocated corporate expenses $ 8.4 $ 16.0 Directly related charges: Insurance programs expenses 1.0 1.9 Medical insurance programs expenses 12.3 24.5 Deferred compensation program expenses 0.3 0.6 Total related-party expenses $ 22.0 $ 43.0 Revenue and other transactions entered into in the ordinary course of business

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jul. 03, 2020
Business Combinations [Abstract]
Fair Values Of The Assets Acquired And Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed as of the acquisition date ($ in millions): January 21, 2020 Assets acquired: Cash $ 2.9 Trade accounts receivable 1.0 Inventories 1.9 Prepaid expenses and other current assets 0.2 Property, plant and equipment 0.5 Goodwill 24.4 Other intangible assets 22.3 Total assets acquired 53.2 Liabilities assumed: Trade accounts payable (0.1 ) Accrued expenses and other liabilities (9.4 ) Total liabilities assumed (9.5 ) Total net assets acquired $ 43.7

Credit Losses (Tables)

Credit Losses (Tables)	6 Months Ended
	Jul. 03, 2020
Credit Loss [Abstract]
Allowance for Credit Losses	The rollforward of the allowance for credit losses is summarized as follows ($ in millions): Balance at December 31, 2019 $ 22.8 Foreign currency translation (0.7 ) Provision for credit losses 11.6 Write-offs charged against the allowance (3.1 ) Balance at July 3, 2020 $ 30.6

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jul. 03, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	The classes of inventory are summarized as follows ($ in millions): July 3, 2020 December 31, 2019 Finished goods $ 230.3 $ 223.5 Work in process 38.3 36.5 Raw materials 90.3 89.9 Inventories, gross 358.9 349.9 Less: reserve for excess and obsolescence (78.1 ) (72.0 ) Inventories, net $ 280.8 $ 277.9

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jul. 03, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	The classes of property, plant and equipment are summarized as follows ($ in millions): July 3, 2020 December 31, 2019 Land and improvements $ 23.8 $ 23.7 Buildings 173.1 166.9 Machinery and equipment 502.6 502.3 Property, plant and equipment, gross 699.5 692.9 Less: accumulated depreciation (405.2 ) (402.6 ) Property, plant and equipment, net $ 294.3 $ 290.3

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jul. 03, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Rollforward and Carrying Value Of Goodwill	The following is a rollforward of the Company’s goodwill ($ in millions): Specialty Products & Technologies Equipment & Consumables Total Balance at December 31, 2019 $ 2,008.1 $ 1,297.9 $ 3,306.0 Acquisitions 24.4 — 24.4 Foreign currency translation and other 3.0 0.4 3.4 Balance at July 3, 2020 $ 2,035.5 $ 1,298.3 $ 3,333.8

Accrued Expenses And Other Li_2

Accrued Expenses And Other Liabilities (Tables)	6 Months Ended
	Jul. 03, 2020
Accrued expenses and other [Abstract]
The Components of Accrued Expenses and Other Liabilities	Accrued expenses and other liabilities were as follows ($ in millions): July 3, 2020 December 31, 2019 Current Noncurrent Current Noncurrent Compensation and benefits $ 111.8 $ 11.7 $ 151.2 $ 8.9 Employee severance and other benefits 37.3 0.5 5.6 — Pension benefits 8.5 89.9 8.5 89.4 Income and other taxes 12.5 283.2 39.3 254.0 Contract liabilities 43.1 3.9 52.6 4.4 Sales and product allowances 50.9 0.8 68.8 0.7 Loss contingencies 62.7 29.0 57.5 29.1 Other 92.6 21.9 87.1 12.8 Total $ 419.4 $ 440.9 $ 470.6 $ 399.3

Hedging Transactions And Deri_2

Hedging Transactions And Derivative Financial Instruments (Tables)	6 Months Ended
	Jul. 03, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments, Gain (Loss)	The following table summarizes the notional values as of July 3, 2020 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended July 3, 2020 ($ in millions): Notional Amount (Loss) Gain Recognized in OCI Three Months Ended July 3, 2020 Interest rate contracts $ 650.0 $ — Foreign currency contracts 650.0 (27.3 ) Foreign currency denominated debt 674.9 (26.2 ) Total $ 1,974.9 $ (53.5 ) Notional Amount (Loss) Gain Recognized in OCI Six Months Ended July 3, 2020 Interest rate contracts $ 650.0 $ (11.7 ) Foreign currency contracts 650.0 9.7 Foreign currency denominated debt 674.9 (2.0 ) Total $ 1,974.9 $ (4.0 )
Schedule of Notional Amounts of Outstanding Derivative Positions	The following table summarizes the notional values as of July 3, 2020 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended July 3, 2020 ($ in millions): Notional Amount (Loss) Gain Recognized in OCI Three Months Ended July 3, 2020 Interest rate contracts $ 650.0 $ — Foreign currency contracts 650.0 (27.3 ) Foreign currency denominated debt 674.9 (26.2 ) Total $ 1,974.9 $ (53.5 ) Notional Amount (Loss) Gain Recognized in OCI Six Months Ended July 3, 2020 Interest rate contracts $ 650.0 $ (11.7 ) Foreign currency contracts 650.0 9.7 Foreign currency denominated debt 674.9 (2.0 ) Total $ 1,974.9 $ (4.0 )
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The Company’s derivative instruments, as well as its non-derivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Condensed Consolidated Balance Sheets as follows ($ in millions): July 3, 2020 December 31, 2019 Derivative assets: Prepaid expenses and other current assets $ — $ 0.1 Other long-term assets $ 3.3 $ — Derivative liabilities: Accrued expense and other liabilities $ 3.2 $ 8.9 Other long-term liabilities $ 10.9 $ — Non-derivative hedging instruments: Long-term debt $ 674.9 $ 672.9

Fair Value Measurements (Table

Fair Value Measurements (Tables)	6 Months Ended
	Jul. 03, 2020
Fair Value Disclosures [Abstract]
Schedule of Financial Assets And Liabilities At Carrying and Fair Value	The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions): July 3, 2020 December 31, 2019 Carrying Amount Fair Value Carrying Amount Fair Value Assets: Cross-currency swap derivative contracts $ 3.3 $ 3.3 $ — $ — Interest rate swap derivative contracts $ — $ — $ 0.1 $ 0.1 Liabilities: Cross-currency swap derivative contracts $ 2.5 $ 2.5 $ 8.9 $ 8.9 Interest rate swap derivative contracts $ 11.6 $ 11.6 $ — $ — Long-term debt, excluding convertible senior notes due 2025 $ 1,321.0 $ 1,321.0 $ 1,321.0 $ 1,321.0 Convertible senior notes due 2025 $ 401.2 $ 644.2 $ — $ — A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Quoted Prices in Active Market (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total July 3, 2020: Assets: Cross-currency swap derivative contracts $ — $ 3.3 $ — $ 3.3 Liabilities: Cross-currency swap derivative contracts $ — $ 2.5 $ — $ 2.5 Interest rate swap derivative contracts $ — $ 11.6 $ — $ 11.6 Deferred compensation plans $ — $ 9.4 $ — $ 9.4 December 31, 2019: Assets: Interest rate swap derivative contracts $ — $ 0.1 $ — $ 0.1 Liabilities: Cross-currency swap derivative contracts $ — $ 8.9 $ — $ 8.9 Deferred compensation plans $ — $ 7.2 $ — $ 7.2

Pension And Other Benefit Pla_2

Pension And Other Benefit Plans (Tables) - Defined benefit pension plans	6 Months Ended
	Jul. 03, 2020
Defined Benefit Plan Disclosure [Line Items]
Schedule of Net Benefit Costs	The following sets forth the components of the Company’s net periodic benefit costs of the defined benefit pension plans ($ in millions): Components of net periodic pension cost: Three Month Period Ended Six Month Period Ended ($ in millions) July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Service cost $ (2.6 ) $ (2.3 ) $ (5.2 ) $ (4.6 ) Interest cost (0.4 ) (0.6 ) (0.8 ) (1.1 ) Expected return on plan assets 0.9 0.8 1.8 1.6 Amortization of initial net obligation (0.1 ) — (0.2 ) (0.1 ) Amortization of prior service credit 0.1 — 0.2 — Amortization of actuarial loss (0.4 ) (0.1 ) (0.8 ) (0.2 ) Curtailment and settlement gains recognized — 1.2 — 1.2 Net periodic pension cost $ (2.5 ) $ (1.0 ) $ (5.0 ) $ (3.2 )
Schedule of Defined Benefit Plans Disclosures	The net periodic benefit costs are reflected in the following captions in the accompanying Condensed Consolidated and Combined Statements of Operations ($ in millions): Three Month Period Ended Six Month Period Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Service cost: Selling, general and administrative expenses $ (2.6 ) $ (2.3 ) $ (5.2 ) $ (4.6 ) Other net periodic pension costs: Nonoperating income (expense), net 0.1 1.3 0.2 1.4 Total $ (2.5 ) $ (1.0 ) $ (5.0 ) $ (3.2 )

Commitments And Contingencies (

Commitments And Contingencies (Tables)	6 Months Ended
	Jul. 03, 2020
Commitments and Contingencies Disclosure [Abstract]
Warranty Accrual	The following is a rollforward of the Company’s accrued warranty liability ($ in millions): Balance at December 31, 2019 $ 9.6 Accruals for warranties issued during the year 7.4 Payments made (7.3 ) Effect of foreign currency translation (0.1 ) Balance at July 3, 2020 $ 9.6

Debt and Credit Facilities (Tab

Debt and Credit Facilities (Tables)	6 Months Ended
	Jul. 03, 2020
Debt Disclosure [Abstract]
Components Of Debt	The components of the Company’s debt were as follows ($ in millions): July 3, 2020 December 31, 2019 Senior term loan facility due 2022 ($650.0 million aggregate principal amount) (the “Term Loan Facility”), net of deferred debt issuance costs of $2.3 million and $1.3 million, respectively $ 647.7 $ 648.7 Senior euro term loan facility due 2022 (€600.0 million aggregate principal amount) (the “Euro Term Loan Facility”), net of deferred debt issuance costs of $1.7 million and $0.9 million, respectively 673.2 672.0 Senior multi-currency revolving credit facility ($250.0 million borrowing capacity) (the “Revolving Credit Facility”) 249.8 — Convertible senior notes, net of deferred debt issuance costs of $11.7 million and unamortized discount of $104.6 million 401.2 — Other 3.8 4.2 Total debt 1,975.7 1,324.9 Less: current portion (253.5 ) (3.9 ) Long-term debt $ 1,722.2 $ 1,321.0
Components of Note Interest Expense	The following table sets forth total interest expense recognized related to the Notes ($ in millions): Three and Six Months Ended July 3, 2020 Contractual interest expense $ 1.4 Amortization of debt issuance costs 0.2 Amortization of debt discount 2.0 Total interest expense $ 3.6

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jul. 03, 2020
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The changes in accumulated other comprehensive loss by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended July 3, 2020 Balance at April 3, 2020 $ (153.6 ) $ (8.8 ) $ (27.5 ) $ (189.9 ) Other comprehensive income before reclassifications: Increase 19.9 — — 19.9 Income tax impact 13.2 — — 13.2 Other comprehensive income before reclassifications, net of income taxes 33.1 — — 33.1 Amounts reclassified from accumulated other comprehensive loss: Increase — — 0.3 0.3 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — 0.3 0.3 Net current period other comprehensive income, net of income taxes 33.1 — 0.3 33.4 Balance at July 3, 2020 $ (120.5 ) $ (8.8 ) $ (27.2 ) $ (156.5 ) Foreign Currency Translation Adjustments Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended June 28, 2019 Balance at March 29, 2019 $ (112.1 ) $ — $ (3.8 ) $ (115.9 ) Other comprehensive income before reclassifications: Increase 31.2 — — 31.2 Other comprehensive loss before reclassifications, net of income taxes 31.2 — — 31.2 Amounts reclassified from accumulated other comprehensive loss: Decrease — — (1.1 ) (1.1 ) Income tax impact — — 0.4 0.4 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.7 ) (0.7 ) Net current period other comprehensive income (loss), net of income taxes 31.2 — (0.7 ) 30.5 Balance at June 28, 2019 $ (80.9 ) $ — $ (4.5 ) $ (85.4 ) Foreign Currency Translation Adjustments Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended July 3, 2020 Balance at December 31, 2019 $ (116.4 ) $ 0.1 $ (27.9 ) $ (144.2 ) Other comprehensive loss before reclassifications: Decrease (2.2 ) (11.7 ) — (13.9 ) Income tax impact (1.9 ) 2.8 — 0.9 Other comprehensive loss before reclassifications, net of income taxes (4.1 ) (8.9 ) — (13.0 ) Amounts reclassified from accumulated other comprehensive loss: Increase — — 0.8 0.8 Income tax impact — — (0.1 ) (0.1 ) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — 0.7 0.7 Net current period other comprehensive (loss) income, net of income taxes (4.1 ) (8.9 ) 0.7 (12.3 ) Balance at July 3, 2020 $ (120.5 ) $ (8.8 ) $ (27.2 ) $ (156.5 ) Foreign Currency Translation Adjustments Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended June 28, 2019 Balance at December 31, 2018 $ (74.3 ) $ — $ (3.9 ) $ (78.2 ) Other comprehensive loss before reclassifications: Decrease (6.6 ) — — (6.6 ) Other comprehensive loss before reclassifications, net of income taxes (6.6 ) — — (6.6 ) Amounts reclassified from accumulated other comprehensive loss: Decrease — — (0.9 ) (a) (0.9 ) Income tax impact — — 0.3 0.3 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.6 ) (0.6 ) Net current period other comprehensive loss, net of income taxes (6.6 ) — (0.6 ) (7.2 ) Balance at June 28, 2019 $ (80.9 ) $ — $ (4.5 ) $ (85.4 )

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jul. 03, 2020
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue by geographical region and revenue type	The following tables present the Company’s revenues disaggregated by geographical region for the three and six months ended July 3, 2020 and June 28, 2019 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenues. The Company has historically defined emerging markets as developing markets of the world, which prior to the COVID-19 pandemic, have experienced extended periods of accelerated growth in gross domestic product and infrastructure, which includes Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not emerging markets. Specialty Products & Technologies Equipment & Consumables Total Three Months Ended July 3, 2020 Geographical region: North America $ 77.9 $ 84.2 $ 162.1 Western Europe 41.0 32.8 73.8 Other developed markets 15.8 12.2 28.0 Emerging markets 49.9 48.2 98.1 Total $ 184.6 $ 177.4 $ 362.0 Three Months Ended June 28, 2019 Geographical region: North America $ 152.3 $ 187.9 $ 340.2 Western Europe 83.2 72.9 $ 156.1 Other developed markets 24.0 21.0 $ 45.0 Emerging markets 87.8 83.0 170.8 Total $ 347.3 $ 364.8 $ 712.1 Specialty Products & Technologies Equipment & Consumables Total Six Months Ended July 3, 2020 Geographical region: North America $ 206.2 $ 225.6 $ 431.8 Western Europe 103.7 90.7 194.4 Other developed markets 37.0 28.7 65.7 Emerging markets 110.3 107.0 217.3 Total $ 457.2 $ 452.0 $ 909.2 Six Months Ended June 28, 2019 Geographical region: North America $ 301.9 $ 336.8 $ 638.7 Western Europe 172.6 143.6 $ 316.2 Other developed markets 46.8 38.6 $ 85.4 Emerging markets 174.8 156.7 331.5 Total $ 696.1 $ 675.7 $ 1,371.8 Sales by major product group ($ in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Consumables $ 255.3 $ 492.8 $ 633.2 $ 953.6 Equipment 106.7 219.3 276.0 418.2 Total $ 362.0 $ 712.1 $ 909.2 $ 1,371.8

Restructuring Activities (Tabl

Restructuring Activities (Tables)	6 Months Ended
	Jul. 03, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The Company initiated restructuring related activities during the six months ended July 3, 2020. The related liability, which is included in accrued liabilities in the Condensed Consolidated Balance Sheets, is summarized below ($ in millions): Employee Severance Facility Exit Total Balance at December 31, 2019 $ 5.6 $ — $ 5.6 Costs incurred 45.6 7.3 52.9 Paid/settled (15.5 ) (5.2 ) (20.7 ) Balance at July 3, 2020 $ 35.7 $ 2.1 $ 37.8
Schedule of Restructuring Reserve by Type of Cost	Restructuring related charges recorded for the three and six months ended July 3, 2020 and June 28, 2019, by segment were as follows ($ in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Specialty Products & Technologies $ 15.7 $ 3.5 $ 16.5 $ 3.2 Equipment & Consumables 41.2 1.3 52.0 3.6 Other 3.0 — 3.7 — Total $ 59.9 $ 4.8 $ 72.2 $ 6.8 The restructuring related charges incurred during the three and six months ended July 3, 2020 and June 28, 2019, are reflected in the following captions in the accompanying Condensed Consolidated and Combined Statements of Operations ($ in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Cost of sales $ 23.9 $ 0.9 $ 26.7 $ 1.8 Selling, general and administrative expenses 36.0 3.9 45.5 5.0 Total $ 59.9 $ 4.8 $ 72.2 $ 6.8

(Loss) Earnings Per Share (Tabl

(Loss) Earnings Per Share (Tables)	6 Months Ended
	Jul. 03, 2020
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings per Share	The table below presents the computation of basic and diluted (loss) earnings per share (in millions, except per share amounts): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Numerator: Net (loss) income $ (93.5 ) $ 61.5 $ (110.7 ) $ 99.4 Denominator: Weighted-average common shares outstanding used in basic and diluted (loss) earnings per share 159.5 127.9 159.3 127.9 (Loss) earnings per share: Basic and diluted $ (0.59 ) $ 0.48 $ (0.69 ) $ 0.78
Securities Not Included in the Computation of Diluted (Loss) Income per Share	The following table presents outstanding securities not included in the computation of diluted (loss) income per share, because their effect was anti-dilutive (in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Stock-based awards 8.4 — 7.1 —

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jul. 03, 2020
Segment Reporting [Abstract]
Segment Results	Segment related information is shown below ($ in millions): Three Months Ended Six Months Ended July 3, 2020 June 28, 2019 July 3, 2020 June 28, 2019 Sales: Specialty Products & Technologies $ 184.6 $ 347.3 $ 457.2 $ 696.1 Equipment & Consumables 177.4 364.8 452.0 675.7 Total $ 362.0 $ 712.1 $ 909.2 $ 1,371.8 Operating (loss) profit and reconciliation to (loss) income before income taxes: Specialty Products & Technologies $ (19.2 ) $ 54.5 $ (11.4 ) $ 120.6 Equipment & Consumables (53.8 ) 29.2 (73.1 ) 17.0 Other (34.9 ) (7.8 ) (48.4 ) (16.8 ) Operating (loss) profit (107.9 ) 75.9 (132.9 ) 120.8 Nonoperating income (expense): Other income 0.1 1.3 0.2 1.4 Interest expense, net (14.5 ) — (17.8 ) — (Loss) income before income taxes $ (122.3 ) $ 77.2 $ (150.5 ) $ 122.2 July 3, 2020 December 31, 2019 Identifiable assets: Specialty Products & Technologies $ 3,693.5 $ 3,662.5 Equipment & Consumables 2,118.1 2,256.6 Other 853.6 239.2 Total $ 6,665.2 $ 6,158.3

Related-Party Transactions (Tab

Related-Party Transactions (Tables)	6 Months Ended
	Jul. 03, 2020
Related Party Transactions [Abstract]
Related Party Expenses	The amounts of related-party expenses allocated to the Company from Danaher for the three and six months ended June 28, 2019, were as follows ($ in millions): Three Months Ended Six Months Ended June 28, 2019 June 28, 2019 Allocated corporate expenses $ 8.4 $ 16.0 Directly related charges: Insurance programs expenses 1.0 1.9 Medical insurance programs expenses 12.3 24.5 Deferred compensation program expenses 0.3 0.6 Total related-party expenses $ 22.0 $ 43.0

Business and Basis of Present_2

Business and Basis of Presentation (Narrative) (Details) $ / shares in Units, shares in Millions, $ in Millions	Sep. 20, 2019USD ($)$ / sharesshares	Jul. 03, 2020Segment
Business Acquisition [Line Items]
Issuance of common stock (in shares)	30.8
Payments to acquire business | $	$ 2,000
Common stock, shares issued (in shares)	127.9
Number of business segments (in segments) | Segment		2
IPO
Business Acquisition [Line Items]
Issuance of common stock (in shares)	30.8
Percentage of outstanding share issues in sale of stock	19.40%
Price per share (in dollars per share) | $ / shares	$ 22
Proceeds from issuance IPO | $	$ 643

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ in Millions	Jan. 21, 2020	Jul. 03, 2020	Jul. 03, 2020
Business Acquisition [Line Items]
Acquisitions			$ 24.4
Matricel
Business Acquisition [Line Items]
Consideration transferred	$ 44
Acquisitions		$ (0.8)
Weighted average amortization period			10 years

Acquisitions (Fair Values Of Th

Acquisitions (Fair Values Of The Assets Acquired And Liabilities) (Details) - USD ($) $ in Millions	Jul. 03, 2020	Jan. 21, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill	$ 3,333.8		$ 3,306
Matricel
Business Acquisition [Line Items]
Cash		$ 2.9
Trade accounts receivable		1
Inventories		1.9
Prepaid expenses and other current assets		0.2
Property, plant and equipment		0.5
Goodwill		24.4
Other intangible assets		22.3
Total assets acquired		53.2
Trade accounts payable		(0.1)
Accrued expenses and other liabilities		(9.4)
Total liabilities assumed		(9.5)
Total net assets acquired		$ 43.7

Credit Losses (Details)

Credit Losses (Details)	6 Months Ended
	Jul. 03, 2020segment
Credit Loss [Abstract]
Number of portfolio segments (in segments)	1

Credit Losses (Allowance for Cr

Credit Losses (Allowance for Credit Losses) (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance at December 31, 2019	$ 22.8
Foreign currency translation	(0.7)
Provision for credit losses	11.6	$ 3.1
Write-offs charged against the allowance	(3.1)
Balance at July 3, 2020	$ 30.6

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 230.3	$ 223.5
Work in process	38.3	36.5
Raw materials	90.3	89.9
Inventories, gross	358.9	349.9
Less: reserve for excess and obsolescence	(78.1)	(72)
Inventories, net	$ 280.8	$ 277.9

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 699.5	$ 692.9
Less: accumulated depreciation	(405.2)	(402.6)
Property, plant and equipment, net	294.3	290.3
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	23.8	23.7
Buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	173.1	166.9
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 502.6	$ 502.3

Goodwill (Rollforward of Goodwi

Goodwill (Rollforward of Goodwill) (Details) $ in Millions	6 Months Ended
	Jul. 03, 2020USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 3,306
Acquisitions	24.4
Foreign currency translation and other	3.4
Ending balance	3,333.8
Specialty Products & Technologies
Goodwill [Roll Forward]
Beginning balance	2,008.1
Acquisitions	24.4
Foreign currency translation and other	3
Ending balance	2,035.5
Equipment & Consumables
Goodwill [Roll Forward]
Beginning balance	1,297.9
Acquisitions	0
Foreign currency translation and other	0.4
Ending balance	$ 1,298.3

Accrued Expenses And Other Li_3

Accrued Expenses And Other Liabilities - (Details) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019
Current
Compensation and benefits	$ 111.8	$ 151.2
Employee severance and other benefits	37.3	5.6
Pension benefits	8.5	8.5
Income and other taxes	12.5	39.3
Contract liabilities	43.1	52.6
Sales and product allowances	50.9	68.8
Loss contingencies	62.7	57.5
Other	92.6	87.1
Total	419.4	470.6
Noncurrent
Compensation and benefits	11.7	8.9
Employee severance and other benefits	0.5	0
Pension benefits	89.9	89.4
Income and other taxes	283.2	254
Contract liabilities	3.9	4.4
Sales and product allowances	0.8	0.7
Loss contingencies	29	29.1
Other	21.9	12.8
Total	$ 440.9	$ 399.3

Hedging Transactions And Deri_3

Hedging Transactions And Derivative Financial Instruments (Narrative) (Details)	Jul. 03, 2020USD ($)	Jul. 03, 2020EUR (€)	Dec. 31, 2019USD ($)	Sep. 20, 2019USD ($)	Sep. 20, 2019EUR (€)
Derivative [Line Items]
Long-term debt	$ 1,975,700,000		$ 1,324,900,000
US term loan due 2022
Derivative [Line Items]
Long-term debt	647,700,000		648,700,000	$ 650,000,000
Term loan	650,000,000			$ 650,000,000
Euro term loan due 2022
Derivative [Line Items]
Long-term debt	$ 673,200,000		$ 672,000,000
Term loan | €		€ 600,000,000			€ 600,000,000

Hedging Transactions And Deri_4

Hedging Transactions And Derivative Financial Instruments (Summary of Notional Values and Pretax Impact in Fair Values of Net Investment Hedges) (Details) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 03, 2020USD ($)	Jul. 03, 2020USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	$ 1,974.9	$ 1,974.9
(Loss) Gain Recognized in OCI	(53.5)	(4)
Net investment hedging | Interest rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	650	650
(Loss) Gain Recognized in OCI	0	(11.7)
Net investment hedging | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	650	650
(Loss) Gain Recognized in OCI	(27.3)	9.7
Net investment hedging | Foreign currency denominated debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	674.9	674.9
(Loss) Gain Recognized in OCI	$ (26.2)	$ (2)

Hedging Transactions And Deri_5

Hedging Transactions And Derivative Financial Instruments (Derivative and Nonderivative Debt Instruments) (Details) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019
Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Derivative assets:	$ 0	$ 0.1
Other long-term assets
Derivatives, Fair Value [Line Items]
Derivative assets:	3.3	0
Accrued expense and other liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities:	3.2	8.9
Other long-term liabilities
Derivatives, Fair Value [Line Items]
Derivative liabilities:	10.9	0
Long-term debt
Derivatives, Fair Value [Line Items]
Non-derivative hedging instruments:	$ 674.9	$ 672.9

Fair Value Measurements - (Fina

Fair Value Measurements - (Financial Assets and Liabilities Carried at Fair Value) (Details) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019
Liability
Liabilities
Noncurrent deferred compensation liability	$ 9.4	$ 7.2
Liability | Quoted Prices in Active Market (Level 1)
Liabilities
Noncurrent deferred compensation liability	0	0
Liability | Significant Other Observable Inputs (Level 2)
Liabilities
Noncurrent deferred compensation liability	9.4	7.2
Liability | Significant Unobservable Inputs (Level 3)
Liabilities
Noncurrent deferred compensation liability	0	0
Cross-currency swap derivative contracts
Assets
Swap derivate contract asset	3.3
Liabilities
Swap derivative contract liability	2.5	8.9
Cross-currency swap derivative contracts | Quoted Prices in Active Market (Level 1)
Assets
Swap derivate contract asset	0
Liabilities
Swap derivative contract liability	0	0
Cross-currency swap derivative contracts | Significant Other Observable Inputs (Level 2)
Assets
Swap derivate contract asset	3.3
Liabilities
Swap derivative contract liability	2.5	8.9
Cross-currency swap derivative contracts | Significant Unobservable Inputs (Level 3)
Assets
Swap derivate contract asset	0
Liabilities
Swap derivative contract liability	0	0
Interest rate swap derivative contracts
Assets
Swap derivate contract asset		0.1
Liabilities
Swap derivative contract liability	11.6
Interest rate swap derivative contracts | Quoted Prices in Active Market (Level 1)
Assets
Swap derivate contract asset		0
Liabilities
Swap derivative contract liability	0
Interest rate swap derivative contracts | Significant Other Observable Inputs (Level 2)
Assets
Swap derivate contract asset		0.1
Liabilities
Swap derivative contract liability	11.6
Interest rate swap derivative contracts | Significant Unobservable Inputs (Level 3)
Assets
Swap derivate contract asset		$ 0
Liabilities
Swap derivative contract liability	$ 0

Fair Value Measurements - (Fair

Fair Value Measurements - (Fair Value of Financial Instruments) (Details) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding convertible senior notes due 2025	$ 1,321	$ 1,321
Convertible senior notes due 2025	401.2	0
Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, excluding convertible senior notes due 2025	1,321	1,321
Convertible senior notes due 2025	644.2	0
Cross-currency swap derivative contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets:	3.3
Derivative liabilities:	2.5	8.9
Cross-currency swap derivative contracts | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets:	3.3	0
Derivative liabilities:	2.5	8.9
Cross-currency swap derivative contracts | Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets:	3.3	0
Derivative liabilities:	2.5	8.9
Interest rate swap derivative contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets:		0.1
Derivative liabilities:	11.6
Interest rate swap derivative contracts | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets:	0	0.1
Derivative liabilities:	11.6	0
Interest rate swap derivative contracts | Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets:	0	0.1
Derivative liabilities:	$ 11.6	$ 0

Pension And Other Benefit Pla_3

Pension And Other Benefit Plans - (Components of Net Periodic Benefit Cost of Defined Benefit Pension Pans) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ (2.6)	$ (2.3)	$ (5.2)	$ (4.6)
Net periodic pension cost	(2.5)	(1)	(5)	(3.2)
Defined benefit pension plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	(2.6)	(2.3)	(5.2)	(4.6)
Interest cost	(0.4)	(0.6)	(0.8)	(1.1)
Expected return on plan assets	0.9	0.8	1.8	1.6
Amortization of initial net obligation	(0.1)	0	(0.2)	(0.1)
Amortization of prior service credit	0.1	0	0.2	0
Amortization of actuarial loss	(0.4)	(0.1)	(0.8)	(0.2)
Curtailment and settlement gains recognized	0	1.2	0	1.2
Net periodic pension cost	$ (2.5)	$ (1)	$ (5)	$ (3.2)

Pension And Other Benefit Pla_4

Pension And Other Benefit Plans - (Components of Net Periodic Benefit Cost Reflected in the Consolidated Condensed Statement of Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Retirement Benefits [Abstract]
Service cost:	$ (2.6)	$ (2.3)	$ (5.2)	$ (4.6)
Other net periodic pension costs:
Nonoperating income (expense)	0.1	1.3	0.2	1.4
Net periodic pension cost	$ (2.5)	$ (1)	$ (5)	$ (3.2)

Commitments And Contingencies_2

Commitments And Contingencies (Narrative) (Details)	6 Months Ended
	Jul. 03, 2020
Commitments and Contingencies Disclosure [Abstract]
Product warranty period	90 days

Commitments And Contingencies_3

Commitments And Contingencies (Warranty Accrual) (Details) $ in Millions	6 Months Ended
	Jul. 03, 2020USD ($)
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at December 31, 2019	$ 9.6
Accruals for warranties issued during the year	7.4
Payments made	(7.3)
Effect of foreign currency translation	(0.1)
Balance at July 3, 2020	$ 9.6

Litigation And Contingencies (N

Litigation And Contingencies (Narrative) (Details) - USD ($) $ in Millions	Jul. 03, 2020	Dec. 31, 2019	Oct. 06, 2015
Commitments and Contingencies Disclosure [Abstract]
Accrual for legal matters	$ 92	$ 87
Loss contingency, estimate of possible loss			$ 30

Debt and Credit Facilities (Com

Debt and Credit Facilities (Components Of Debt) (Details)	Jul. 03, 2020USD ($)	Jul. 03, 2020EUR (€)	May 21, 2020USD ($)	Dec. 31, 2019USD ($)	Sep. 20, 2019USD ($)	Sep. 20, 2019EUR (€)
Debt Instrument [Line Items]
Total debt	$ 1,975,700,000			$ 1,324,900,000
Less: current portion	(253,500,000)			(3,900,000)
Long-term debt	1,722,200,000			1,321,000,000
Senior term loan facility due 2022 ($650.0 million aggregate principal amount) (the “Term Loan Facility”), net of deferred debt issuance costs of $2.3 million and $1.3 million, respectively
Debt Instrument [Line Items]
Term loan	650,000,000				$ 650,000,000
Debt issuance costs	2,300,000			1,300,000
Total debt	647,700,000			648,700,000	$ 650,000,000
Senior euro term loan facility due 2022 (€600.0 million aggregate principal amount) (the “Euro Term Loan Facility”), net of deferred debt issuance costs of $1.7 million and $0.9 million, respectively
Debt Instrument [Line Items]
Term loan | €		€ 600,000,000				€ 600,000,000
Debt issuance costs	1,700,000			900,000
Total debt	673,200,000			672,000,000
Senior multi-currency revolving credit facility ($250.0 million borrowing capacity) (the “Revolving Credit Facility”)
Debt Instrument [Line Items]
Revolving credit facility maximum borrowing capacity	250,000,000
Total debt	249,800,000			0
Other
Debt Instrument [Line Items]
Total debt	3,800,000			4,200,000
Convertible Debt | Convertible senior notes, net of deferred debt issuance costs of $11.7 million and unamortized discount of $104.6 million
Debt Instrument [Line Items]
Term loan			$ 518,000,000
Debt issuance costs	11,700,000		$ 12,000,000
Unamortized discount	104,600,000
Interest rate			2.375%
Total debt	$ 401,200,000		$ 411,000,000	$ 0

Debt and Credit Facilities (Nar

Debt and Credit Facilities (Narrative) (Details) $ / shares in Units, shares in Millions	May 21, 2020USD ($)Trading_day$ / sharesshares	May 06, 2020USD ($)	Sep. 20, 2019USD ($)	Jul. 03, 2020USD ($)$ / shares	Jul. 03, 2020USD ($)$ / shares	Jun. 28, 2019USD ($)	Jul. 03, 2020EUR (€)	Dec. 31, 2019USD ($)	Sep. 20, 2019EUR (€)
Debt Instrument [Line Items]
Unamortized debt issuance costs				$ 120,000,000	$ 120,000,000
Total borrowings under term loan			$ 1,300,000,000
Senior unsecured revolving credit facility			$ 250,000,000
Payments of debt restructuring		$ 3,000,000
Deferred debt restructuring costs		$ 2,000,000
Proceeds from convertible debt					517,500,000	$ 0
Long-term debt				1,975,700,000	1,975,700,000			$ 1,324,900,000
US term loan due 2022
Debt Instrument [Line Items]
Debt instrument, term			3 years
Term loan			$ 650,000,000	$ 650,000,000	$ 650,000,000
Loan facility interest rates				3.70%	3.40%
Long-term debt			$ 650,000,000	$ 647,700,000	$ 647,700,000			648,700,000
Debt issuance costs				$ 2,300,000	$ 2,300,000			1,300,000
Euro term loan due 2022
Debt Instrument [Line Items]
Debt instrument, term			3 years
Term loan | €							€ 600,000,000		€ 600,000,000
Loan facility interest rates				2.50%	1.80%
Long-term debt				$ 673,200,000	$ 673,200,000			672,000,000
Debt issuance costs				1,700,000	1,700,000			900,000
Senior multi-currency revolving credit facility ($250.0 million borrowing capacity) (the “Revolving Credit Facility”)
Debt Instrument [Line Items]
Revolving credit facility maximum borrowing capacity				250,000,000	250,000,000
Revolving credit facility increase				$ 200,000,000	$ 200,000,000
Loan facility interest rates				3.10%	3.00%
Senior multi-currency revolving credit facility ($250.0 million borrowing capacity) (the “Revolving Credit Facility”) | Standby letters of credit
Debt Instrument [Line Items]
Revolving credit facility maximum borrowing capacity				$ 20,000,000	$ 20,000,000
Convertible Debt | 2.375% Convertible Senior Notes Over Allotment Option
Debt Instrument [Line Items]
Term loan	$ 68,000,000
Convertible Debt | Convertible senior notes, net of deferred debt issuance costs of $11.7 million and unamortized discount of $104.6 million
Debt Instrument [Line Items]
Term loan	518,000,000
Debt issuance costs	3,000,000
Proceeds from convertible debt	$ 503,000,000
Interest rate	2.375%
Conversion ratio	0.0475862
Conversion price (in USD per share) | $ / shares	$ 21.01			$ 23.79	$ 23.79
Repurchase price (as a percentage of principal)	100.00%
Percentage stock price trigger	130.00%
Threshold of trading days | Trading_day	20
Threshold of consecutive trading days | Trading_day	30
Long-term debt	$ 411,000,000			$ 401,200,000	$ 401,200,000			$ 0
Fair value of convertible debt				644,000,000	644,000,000
Equity component	107,000,000
Debt issuance costs	12,000,000			$ 11,700,000	$ 11,700,000
Net deferred tax liability	$ 20,000,000
Effective interest rate				7.30%	7.30%		7.30%
If-converted value in excess of principal					$ 9,000,000
Convertible Debt | 2.375% Convertible Senior Notes, Capped Calls
Debt Instrument [Line Items]
Conversion price (in USD per share) | $ / shares	$ 23.79
Convertible note hedge, price per common share (in USD per share) | $ / shares	$ 21.01
Convertible note hedge (in shares) | shares	2.9
Convertible note hedge	$ 21,000,000
Line of Credit | Senior multi-currency revolving credit facility ($250.0 million borrowing capacity) (the “Revolving Credit Facility”)
Debt Instrument [Line Items]
Debt instrument, term			5 years

Debt and Credit Facilities (Int

Debt and Credit Facilities (Interest Expense) (Details) - Convertible Debt - 2.375% Convertible Senior Notes $ in Millions	6 Months Ended
	Jul. 03, 2020USD ($)
Debt Instrument [Line Items]
Contractual interest expense	$ 1.4
Amortization of debt issuance costs	0.2
Amortization of debt discount	2
Total interest expense	$ 3.6

Stock Transactions (Narrative)

Stock Transactions (Narrative) (Details)	Sep. 20, 2019$ / sharesshares	Sep. 17, 2019shares	Jul. 03, 2020Vote$ / sharesshares	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized (in shares)	500,000,000		500,000,000	500,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01	$ 0.01
Preferred shares authorized (in shares)	15,000,000		15,000,000	15,000,000
Common stock, shares outstanding (in shares)			159,300,000	158,700,000
Preferred shares issued (in shares)			0	0
Preferred shares outstanding (in shares)			0	0
Common stock voting rights (in votes per share) | Vote			1
Entity
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock previously held by affiliate (in shares)		100
Common stock, shares outstanding (in shares)		127,900,000
IPO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock (in shares)	30,800,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period			$ 3,542.8
Increase (decrease), before reclassifications	$ 19.9	$ 31.2	(13.9)	$ (6.6)
Income tax impact	13.2		0.9
Other comprehensive income (loss) before reclassifications, net of income taxes	33.1	31.2	(13)	(6.6)
Increase (decrease), reclassified	0.3	(1.1)	0.8	(0.9)
Income tax impact, reclassified		0.4	(0.1)	0.3
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0.3	(0.7)	0.7	(0.6)
Net current period other comprehensive income (loss), net of income taxes	33.4	30.5	(12.3)	(7.2)
Balance, end of period	3,495.9		3,495.9
Foreign Currency Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(153.6)	(112.1)	(116.4)	(74.3)
Increase (decrease), before reclassifications	19.9	31.2	(2.2)	(6.6)
Income tax impact	13.2		(1.9)
Other comprehensive income (loss) before reclassifications, net of income taxes	33.1	31.2	(4.1)	(6.6)
Increase (decrease), reclassified	0	0	0	0
Income tax impact, reclassified		0	0	0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0	0	0	0
Net current period other comprehensive income (loss), net of income taxes	33.1	31.2	(4.1)	(6.6)
Balance, end of period	(120.5)	(80.9)	(120.5)	(80.9)
Unrealized Gain (Loss) on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(8.8)	0	0.1	0
Increase (decrease), before reclassifications	0	0	(11.7)	0
Income tax impact	0		2.8
Other comprehensive income (loss) before reclassifications, net of income taxes	0	0	(8.9)	0
Increase (decrease), reclassified	0	0	0	0
Income tax impact, reclassified		0	0	0
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0	0	0	0
Net current period other comprehensive income (loss), net of income taxes	0	0	(8.9)	0
Balance, end of period	(8.8)	0	(8.8)	0
Unrealized Pension Costs
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(27.5)	(3.8)	(27.9)	(3.9)
Increase (decrease), before reclassifications	0	0	0	0
Income tax impact	0		0
Other comprehensive income (loss) before reclassifications, net of income taxes	0	0	0	0
Increase (decrease), reclassified	0.3	(1.1)	0.8	(0.9)
Income tax impact, reclassified		0.4	(0.1)	0.3
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes	0.3	(0.7)	0.7	(0.6)
Net current period other comprehensive income (loss), net of income taxes	0.3	(0.7)	0.7	(0.6)
Balance, end of period	(27.2)	(4.5)	(27.2)	(4.5)
Total Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(189.9)	(115.9)	(144.2)	(78.2)
Balance, end of period	$ (156.5)	$ (85.4)	$ (156.5)	$ (85.4)

Revenue (Disaggregation by Reve

Revenue (Disaggregation by Revenue Type and Geographical Region) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Disaggregation of Revenue [Line Items]
Sales	$ 362	$ 712.1	$ 909.2	$ 1,371.8
North America
Disaggregation of Revenue [Line Items]
Sales	162.1	340.2	431.8	638.7
Western Europe
Disaggregation of Revenue [Line Items]
Sales	73.8	156.1	194.4	316.2
Other developed markets
Disaggregation of Revenue [Line Items]
Sales	28	45	65.7	85.4
Emerging markets
Disaggregation of Revenue [Line Items]
Sales	98.1	170.8	217.3	331.5
Specialty Products & Technologies
Disaggregation of Revenue [Line Items]
Sales	184.6	347.3	457.2	696.1
Specialty Products & Technologies | North America
Disaggregation of Revenue [Line Items]
Sales	77.9	152.3	206.2	301.9
Specialty Products & Technologies | Western Europe
Disaggregation of Revenue [Line Items]
Sales	41	83.2	103.7	172.6
Specialty Products & Technologies | Other developed markets
Disaggregation of Revenue [Line Items]
Sales	15.8	24	37	46.8
Specialty Products & Technologies | Emerging markets
Disaggregation of Revenue [Line Items]
Sales	49.9	87.8	110.3	174.8
Equipment & Consumables
Disaggregation of Revenue [Line Items]
Sales	177.4	364.8	452	675.7
Equipment & Consumables | North America
Disaggregation of Revenue [Line Items]
Sales	84.2	187.9	225.6	336.8
Equipment & Consumables | Western Europe
Disaggregation of Revenue [Line Items]
Sales	32.8	72.9	90.7	143.6
Equipment & Consumables | Other developed markets
Disaggregation of Revenue [Line Items]
Sales	12.2	21	28.7	38.6
Equipment & Consumables | Emerging markets
Disaggregation of Revenue [Line Items]
Sales	48.2	83	107	156.7
Consumables
Disaggregation of Revenue [Line Items]
Sales	255.3	492.8	633.2	953.6
Equipment
Disaggregation of Revenue [Line Items]
Sales	$ 106.7	$ 219.3	$ 276	$ 418.2

Revenue (Narrative) (Details)

Revenue (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 03, 2020	Jul. 03, 2020	Jun. 28, 2019	Dec. 31, 2019
Concentration Risk [Line Items]
Contract liability	$ 47	$ 47		$ 57
Revenue recognized		$ 32	$ 39
Customer Concentration Risk | Revenue Benchmark
Concentration Risk [Line Items]
Concentration risk percentage	13.00%	12.00%

Revenue Remaining Performance O

Revenue Remaining Performance Obligation (Details) $ in Millions	Jul. 03, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 18
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-04
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction	12 months

Restructuring Activities (Sched

Restructuring Activities (Schedule Of Restructuring And Related Costs) (Details) $ in Millions	6 Months Ended
	Jul. 03, 2020USD ($)
Restructuring Reserve [Roll Forward]
Balance at beginning of year	$ 5.6
Costs incurred	52.9
Paid/settled	(20.7)
Balance at end of year	37.8
Employee Severance and Related
Restructuring Reserve [Roll Forward]
Balance at beginning of year	5.6
Costs incurred	45.6
Paid/settled	(15.5)
Balance at end of year	35.7
Facility Exit and Related
Restructuring Reserve [Roll Forward]
Balance at beginning of year	0
Costs incurred	7.3
Paid/settled	(5.2)
Balance at end of year	$ 2.1

Restructuring Activities (Narra

Restructuring Activities (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jul. 03, 2020	Jul. 03, 2020	Jun. 28, 2019
Restructuring Cost and Reserve [Line Items]
Inventory write-off		$ 9	$ 0
Portion of Treatment Unit Business | Disposal by abandonment
Restructuring Cost and Reserve [Line Items]
Non-cash loss on disposal of partial business unit	$ 19
Impairment of intangible assets	9
Inventory write-off	$ 9

Restructuring Activities (Sch_2

Restructuring Activities (Schedule Of Restructuring And Other Related Charges By Segment) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 59.9	$ 4.8	$ 72.2	$ 6.8
Specialty Products & Technologies
Restructuring Cost and Reserve [Line Items]
Costs incurred	15.7	3.5	16.5	3.2
Equipment & Consumables
Restructuring Cost and Reserve [Line Items]
Costs incurred	41.2	1.3	52	3.6
Other
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 3	$ 0	$ 3.7	$ 0

Restructuring Activities (Sch_3

Restructuring Activities (Schedule Of Restructuring Reserve By Type Of Cost) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 59.9	$ 4.8	$ 72.2	$ 6.8
Cost of sales
Restructuring Cost and Reserve [Line Items]
Costs incurred	23.9	0.9	26.7	1.8
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 36	$ 3.9	$ 45.5	$ 5

Income Taxes - (Narrative) (Det

Income Taxes - (Narrative) (Details)	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	23.50%	20.30%	26.40%	18.70%

(Loss) Earnings Per Share (Narr

(Loss) Earnings Per Share (Narrative) (Details) - $ / shares	Sep. 20, 2019	Sep. 17, 2019	Jul. 03, 2020	May 21, 2020
Share Information [Line Items]
Shares of common stock previously held by Danaher (in shares)		100
Issuance of common stock (in shares)	30,800,000
Common Stock
Share Information [Line Items]
Envista stock issued as consideration to Danaher as part of separation agreement (in shares)		127,900,000
2.375% Convertible Senior Notes | Convertible Debt
Share Information [Line Items]
Conversion price (in USD per share)			$ 23.79	$ 21.01

(Loss) Earnings Per Share (Comp

(Loss) Earnings Per Share (Computation of Basic and Diluted Earnings per Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Numerator:
Net (loss) income	$ (93.5)	$ 61.5	$ (110.7)	$ 99.4
Denominator:
Weighted-average common shares outstanding used in basic and diluted (loss) earnings per share (in shares)	159.5	127.9	159.3	127.9
(Loss) earnings per share:
Basic and diluted (in USD per share)	$ (0.59)	$ 0.48	$ (0.69)	$ 0.78

(Loss) Earnings Per Share (Secu

(Loss) Earnings Per Share (Securities Not Included in the Computation of Diluted Loss Income per Share) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Stock-based awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted (loss) income per share (shares)	8.4	0	7.1	0

Segment Information (Segment Re

Segment Information (Segment Results) (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 03, 2020USD ($)	Jun. 28, 2019USD ($)	Jul. 03, 2020USD ($)Segment	Jun. 28, 2019USD ($)	Dec. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments (in segments) | Segment			2
Number of operating segments (in segments) | Segment			2
Sales	$ 362	$ 712.1	$ 909.2	$ 1,371.8
Operating (loss) profit	(107.9)	75.9	(132.9)	120.8
Other income	0.1	1.3	0.2	1.4
Interest expense, net	(14.5)	0	(17.8)	0
(Loss) income before income taxes	(122.3)	77.2	(150.5)	122.2
Assets	6,665.2		6,665.2		$ 6,158.3
Other
Segment Reporting Information [Line Items]
Operating (loss) profit	(34.9)	(7.8)	(48.4)	(16.8)
Assets	853.6		853.6		239.2
Specialty Products & Technologies
Segment Reporting Information [Line Items]
Sales	184.6	347.3	457.2	696.1
Assets	3,693.5		3,693.5		3,662.5
Specialty Products & Technologies | Operating segments
Segment Reporting Information [Line Items]
Sales	184.6	347.3	457.2	696.1
Operating (loss) profit	(19.2)	54.5	(11.4)	120.6
Equipment & Consumables
Segment Reporting Information [Line Items]
Sales	177.4	364.8	452	675.7
Assets	2,118.1		2,118.1		$ 2,256.6
Equipment & Consumables | Operating segments
Segment Reporting Information [Line Items]
Sales	177.4	364.8	452	675.7
Operating (loss) profit	$ (53.8)	$ 29.2	$ (73.1)	$ 17

Related-Party Transactions (Rel

Related-Party Transactions (Related Party Expenses) (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 28, 2019	Jul. 03, 2020	Jun. 28, 2019
Related Party Transaction [Line Items]
License agreement improvement period		2 years
Affiliated Entity
Related Party Transaction [Line Items]
Related party expenses	$ 22		$ 43
Affiliated Entity | Allocated corporate expenses
Related Party Transaction [Line Items]
Related party expenses	8.4		16
Affiliated Entity | Insurance programs expenses
Related Party Transaction [Line Items]
Related party expenses	1		1.9
Affiliated Entity | Medical insurance programs expenses
Related Party Transaction [Line Items]
Related party expenses	12.3		24.5
Affiliated Entity | Deferred compensation program expenses
Related Party Transaction [Line Items]
Related party expenses	$ 0.3		$ 0.6